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IDENTIFICATION AND CHARACTERIZATION OF MODULATORS OF HUMAN 
MRP1 (ABCC1) AND HUMAN MRP2 (ABCC2) EXPRESSION  
VIVIAN OSEI POKU 
2021 
ATP-binding cassette (ABC) transporters are known to play a critical role in conferring 
multidrug resistance (MDR) in various cancers. Several retrospective analyses of 
chemotherapy results have reported high expression of Multidrug Resistance Protein 1 
(MRP1) and  Multidrug Resistance Protein 2 (MRP2)  in tumor cells exhibiting the MDR 
phenotype. High MRP1 and MRP2 expression in cancer patients predict a higher risk of 
treatment failure, resulting in relapse and disease recurrence as well as shortened survival 
rates. The key role of MRP1 and MRP2 play in the development of MDR makes them 
important therapeutic targets that hold a great promise for addressing multidrug resistance 
in cancer cells. Since MRP1 and MRP2 play critical roles in the regulation of various 
cellular pathways by altering the levels of several key signaling molecules, finding ways 
of modulating the activities and expression of these transporters in cancer cells is of great 
clinical interest in oncology research. We identified four novel modulators of MRP1 from 
our initial screening of 30 therapeutic compounds using an In-Cell ELISA assay. Three of 
these compounds; Amuvatinib, SB743921 HCl, TG101348 (SAR302503), which were 
identified to be ATP competitive inhibitors based on their mode of action, decreased MRP1 
expression whereas Felbamate (a recently approved FDA drug) increased MRP1 protein 
expression. Our findings revealed that these ATP competitive inhibitors decreased MRP1-
mediated calcein accumulation. These compounds inhibited the growth of HEK293 MRP1-
xix 
 
overexpressing cells at clinically achievable concentrations, and also reversed MRP1- 
mediated resistance in these cells. Since regulation of the activity of activators and effectors 
of specific biochemical pathways provide a means of regulating downstream signaling, we 
investigated the effect of a novel Tie2 kinase inhibitor  and mTOR inhibitor, Everolimus, 
on MRP1 activity and expression. Tie2 is an activator of the PI3K/Akt pathway (a pathway 
known to modulate MRP1 activity and expression) whereas mTOR is a downstream 
effector of this pathway. We demonstrated using a flow cytometry-based calcein 
accumulation assay, and MTT based reversal resistance studies that Tie2 kinase inhibitor 
and Everolimus can decrease MRP1 mediated calcein efflux and reverse MRP1 mediated 
resistance towards vincristine in HEK293 MRP1-overexpressing cells. Lastly, we 
identified 49 modulators of MRP2 from our initial screening of 372 FDA-approved drugs 
from a recently approved FDA drug library representing 13.17% of total compounds 
screened. Thirty-nine (39) drugs increased MRP2 expression whereas 10 drugs lowered 
expression of MRP2 after drug treatment. Results from this screening reaffirm the 
promiscuous nature of the MRP2 transporter, and how important it is to investigate the 
interaction between both old and newly developed drugs with MRP2. The modulators 
identified from this study would be further characterized in future projects. Overall, our 
findings signify the importance of profiling drug interactions with these transporters, and 
the data obtained would provide essential information to improve combinatorial drug 





1.0 Scope of the Study 
The main objective and significance of this study is to identify and characterize drugs from 
various drug libraries as modulators of Multidrug Resistance Protein 1 (MRP1) and 
Multidrug Resistance Protein 2 (MRP2) protein expression in cancer cells.  This section 
reviews important literature on ATP Binding Cassette (ABC) transporters with a focus on 
the ABCC subfamily, their structure, function, and mode of transport. It also details the 
role of ABC transporters in the development of Multidrug Resistance (MDR), the role of 
modulators in chemotherapy, and some current modulators of ABC transporters as well as 
some mechanisms through which protein expression of ABC transporters can be 
modulated. This chapter also captures relevant literature on common assays employed in 
screening for modulators of ABC transporters such as MRP1 and MRP2. In-cell ELISA 
assay, which was the main high-throughput screening tool used in this present study is 
carefully examined. Finally, this section concludes by detailing the rationale of this present 
study and the essence of identifying modulators of ABC transporters protein expression. It 
also describes how findings from this project can be utilized in curbing multidrug resistance 







1.1 Introduction to ABC transporters 
One of the largest superfamilies of transporters reported to be present in almost every 
kingdom of life is the ATP-binding cassette superfamily of transporters (ABC 
transporters). They are described as a diverse and ubiquitous superfamily of transporters 
encoded by the ABC genes [1]. ABC transporters function basically as primary-active 
transporters, as such they require ATP hydrolysis for their transport activity [2]. These 
transporters were previously known as the traffic ATPases [2]. ABC transporters are 
reported to facilitate the transport of a broad spectrum of molecules ranging from small 
molecules to highly charged and highly hydrophobic molecules such as peptides, lipids, 
vitamins [3, 4]. Based on the direction of transport relative to the cytoplasm, ABC 
transporters can be classified as importers or exporters [5]. This superfamily of transporters 
function as both influx and efflux transporters in prokaryotes, but function mainly as efflux 
transporters in eukaryotes. As influx transporters, they are responsible for the influx or 
transport of nutrients into the cells. Moreover, as efflux transporters, they are responsible 
for the efflux of toxins and drugs across biological membranes [6]. In microorganisms, 
ABC transporters have been associated with the development of antibiotic and antifungal 
resistance [3].  
In humans, 49 ABC transporter proteins have been discovered. These transporters have 
been categorized into seven subfamilies based on their amino acid sequence and protein 
domain (Table 1.0) [7, 8]. ABC transporters have been reported to play key roles in the 
transport of drugs and their metabolites, toxins, steroids, heavy metals as well as aid in 
maintaining physiological homeostasis [9]. ABC transporters are expressed in the lungs, 
kidney, intestines, and at sacred pharmacological regions like the blood-placenta barrier, 
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blood-brain barrier, blood-testis barrier, and the blood-cerebrospinal fluid barrier [10]. 
Mutation in some ABC transporters have been associated with several human genetic 
diseases, and immune deficiencies. Examples include Cystic fibrosis (ABCC7/CFTR), 
Stargardt disease and age-related macular degeneration (ABCA4/ABCR), Tangier disease 
and familial HDL deficiency (ABCA1), Progressive familial intrahepatic cholestasis 
(ABCB11/SPGP), Dubin-Johnson syndrome (ABCC2/MRP2), Pseudoxanthoma 
Elasticum (ABCC6/MRP6), Persistent hypoglycemia of infancy (ABCC8/SUR1), 
Sideroblastic anemia (ABCB7), Adrenoleukodystrophy (ABCD1), Sitosterolemia 




Table 1.1: List of subfamilies and members of ABC superfamily 
Superfamily Subfamily Members 














































Table 1.1 (Continued): List of subfamilies and members of ABC superfamily. 
Superfamily Subfamily Members 




   
ABCE 





 ABCF F1 
F2 
F3 






1.2 Structural organization and function of ABC transporters 
Structural analysis reveals that most ABC transporters consist of two sets of membrane-
spanning domains (MSD1 and MSD2) also referred to as the transmembrane domains 
(TMDs) and two nucleotide-binding domains (NBD1 and NBD2) [12] (Figure 1.1). The 
NBDs consist of two conserved Walker motifs (A and B) regions and a dodecapeptide 
region or linker that lies between the Walker motifs known as the C region. The Walker A 
and Walker B motifs are reported to be pivotal for ATP binding and hydrolysis [13]. The 
Walker A motif specifically binds to ß-γ phosphate of ATP to the Glycine loop of γ- 
phosphate linker, whereas the  Walker B motif interacts with the magnesium ions. Region 
C or the LSGGQ motif serves as the ABC signature motif [14]. A typical MSD consists of 
six transmembrane α-helices. The MSDs are responsible for substrate recognition and 
translocation across biological membranes [9]. In the ABC superfamily, full transporters 
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refer to transporter proteins with at least two MSDs and two NBDs, whereas transporter 
proteins with one of each domain are referred to as half transporters. Recent studies have 
revealed that some ABC transporters like ABCC1/MRP1 and ABCC2/MRP2 possess an 
extra NH2 – proximal membrane-spanning domain known as the MSD0 [15]. The MSD0 
contains five transmembrane helices and is reported to help with the retention and recycling 
of the transporter to the plasma membrane [16] (Figure 1.1).  
 
Figure 1.1 Structure of ABC transporters. 
The membrane-spanning domains; MSD0 (green), MSD1(yellow), MSD2 (red), and 
nucleotide-binding domains (NBDs). [A] The predicted topology of half ABC transporters 
like BRCP/ABCG2. [B] The predicted topology of ABC transporters like ABCB1/P-gp, 
and short MRPs (MRP 4,5,6,8). [C] The predicted topology of ABC transporters having an 
extra MSD (MSD0) like long MRPs (MRP1, 2, 3, 6, and 7). 
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1.3 The ABCC subfamily 
A total of thirteen transporters can be found in this subfamily. These transporters are 
referred to as full transporters and are grouped into the multidrug resistance protein 
subgroup (9 members), and the sulfonylurea receptor subgroup (SURs, 3 members). The 
cystic fibrosis transmembrane conductance regulator (CFTR) can also be found in this 
subfamily [17]. The summary of members of this subfamily is listed in table 1.2. Members 
of the MRP subgroup can further be categorized into long and short MRPs based on their 
predicted topology [18]. The long MRPs are described as transporter proteins that have an 
additional NH2-proximal MSD0 to their set of membrane-spanning domains (MSD1 and 
MSD2), and two nucleotide-binding domains (NBD1 and NBD2) (Figure 1.1). Examples 
of MRPs with this predicted topology include ABCC1/MRP1, ABCC2/MRP2, 
ABCC3/MRP3, ABCC6/MRP6, and ABCC10/MRP7. The short MRPs on the other hand 
consist of two membrane-spanning domains and two nucleotide-binding domains. 
Members with this predicted topology include ABCC4/MRP4, ABCC5/MRP5, 
ABCC11/MRP8, and ABCC12/MRP9 [19]. ABCC6 is reported to be associated with the 
genetic disease, Pseudoxanthoma Elasticum (PXE) [20]. This disease is characterized by 
abnormal accumulation of calcium and other minerals in the elastic fibers of connective 
tissues. Mutations in CFTR that cause protein misfolding and abnormal processing provide 
the molecular basis of genetic disease, Cystic fibrosis [21]. CFTR plays a key role in 
chloride transport. Thus mutation in this gene affects the chloride ion channel function 
resulting in dysregulation of epithelial fluid transport in the lungs, pancreas and in other 
organs leading to Cystic fibrosis.  Loss of ABCC2 activity is also reported to be associated 
with the Dubin-Johnson syndrome which is characterized by hyperbilirubinemia. 
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Moreover, members of the ABCC subfamily like ABCC1 (MRP1) and ABCC2 (MRP2) 
have been associated with the development of multidrug resistance in several carcinomas. 



















ABCC1 MRP1 Ubiquitous (lungs, kidney, 
placenta, blood-brain 
barrier) 
[22, 23]  
ABCC2 MRP2 Canicular membrane of 
hepatocytes. 
Apical membrane of 
proximal renal tubule 
endothelial cells 
[24, 25] 
ABCC3 MRP3 Liver, colon, intestine, 
adrenal gland 
[24] 
ABCC4 MRP4 Prostate, testis, ovary, 
intestine, pancreas, lung 
[11, 26]  
ABCC5 MRP5 Skeletal muscle, brain, 
heart  
[27] 
ABCC6 MRP6 Liver, kidney [28] 
ABCC10 MRP7 Liver, peripheral blood 
cells, intestines 
[29]  
ABCC11 MRP8 Breast, lung, colon, 
prostate, ovary 
[30] 















ABCC8 SUR1 Neuronal cells, pancreatic 
B-cells 
[32] 
ABCC9 SUR2 SUR 2A - cardiac and 
skeletal muscle 




CFTR ABCC7 Apical membrane of 




ABCC13  MRP10 Liver, fetal spleen, colon, 




Multidrug Resistance Protein 1 (MRP1) is a 1531 amino acid integral-membrane protein 
with a molecular weight of 190-kDa, it is encoded by the gene ABCC1 [37]. MRP1 is 
expressed at normal levels in the lungs, kidney, placenta, heart [22, 23], with lower 
expression levels observed in the colon, brain, small intestine, and peripheral blood 
mononuclear cells. High expression levels of the transporter are observed in cells at various 
pharmacological sanctuary sites like the blood-brain barrier, blood-testis barrier, and in the 
basolateral membrane of polarized cells [38] as well as in cells with high proliferative 
status such as the reactive type II pneumocytes in the alveoli of the lungs [39]. MRP1 as 
an ATP-dependent efflux transporter plays a major role in transporting broad spectrum 
substrates. These substrates include organic anions, metalloids (sodium arsenite, potassium 
antimonite), toxicants (aflatoxin B1, methoxychlor) folic acids, bilirubin, vitamins, 
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glutathione and glucuronide-conjugates of steroids, leukotrienes, and prostaglandins B12 
[18, 40, 41]. Endobiotics transported by MRP1 include doxorubicin, vincristine, paclitaxel, 
ritonavir, irinotecan, methotrexate, saquinavir [41]. Due to the ability of MRP1 to transport 
drugs from different multiple families irrespective of their molecular target, structure and 
mode of action, MRP1 has been reported to  regulate the absorption and disposition of 
drugs as well as their metabolites across cells [42]. MRP1 is also reported to be a major 
player in the regulation of several physiological processes like redox homeostasis, steroid 
metabolism, tissue defense and in the etiology of neurodegenerative and cardiovascular 
diseases [43].  
MRP2 (ABCC2) on the other hand is also known as canalicular multi-specific organic 
anion transporter 1 (cMOAT) [44]. It functions as an ATP-dependent unidirectional efflux 
pump and is highly expressed in the liver where it governs the elimination of bilirubin 
glucuronides and drug conjugates into the bile. MRP2 is also involved in renal elimination 
in the kidneys, and distribution of its substrates in the placenta and the gastrointestinal tract 
[45]. It is involved in the transport of numerous clinically important compounds across 
multiple drug classes such as antibiotics, HIV drugs, antihypertensives, and anticancer 
agents as well as conjugates of lipophilic substances with glutathione, glucuronate, and 
sulfate [46]. MRP2 plays a critical role in conferring resistance to various 
chemotherapeutics as such it has been implicated in multidrug resistance (MDR) of several 
cancers like ovarian, colorectal, lung carcinomas. Moreover, the absence of functional 




 As members of the long MRPs subgroup, MRP1 and MRP2 possess two nucleotide-
binding domains (NBDs) and two membrane-spanning domains (MSDs), and an additional 
third N- terminal membrane-spanning domain (MSD0) which comprises of 5 
transmembrane spanning helices  [26, 48] (Figure 1.1[C]). Studies have shown that MSD0 
facilitates interactions between the transporter and other protein partners [49]. Structural 
analysis has shown that when these transporters are not bound to any substrate or ATP, 
they assume an inward-facing conformation, while the NBDs are widely separated and the 
translocation pathway remains continuous with the cytoplasm [50]. On the other hand, the 
MSDs get closer to form a high- affinity substrate binding pocket to which the substrate 
binds. The NBDs move closer to each other and align themselves for dimerization. ATP 
binds to the NBDs, leading to dimerization of the NBDs which causes a conformational 
change that results in rearrangement of the MSDs to the outward-facing conformation of 
the transporter (rotates and opens towards the extracellular space). Sequentially, the 
residues forming the substrate-binding site tend to be pulled apart as the extracellular ends 
of the helices of the MSDs peel outward leading to a significant reduction in the binding 
affinity of the substrate to the transporter. As a result, the substrate is released into the 
extracellular space [50]. ATP hydrolysis begins which causes the dissolution of the closed 
NBD dimer conformation. The MSDs move into the open conformation as ADP (adenosine 
diphosphate) and phosphate is released [2]. A pictorial diagram of the transport mechanism 





Figure 1.2 Mechanism of ATP mediated transport of ABC exporters based on the 
ATP switch model.  
The substrate (blue rectangle) binds to the high-affinity binding pocket formed by the 
MSDs (yellow and red). This leads to a conformational change in the NBDs (green and 
pink), ATP (turquoise hexagon) binds and subsequent NBDs dimer closure occurs. A 
conformational change in the MSDs transpires upon the NBDs dimer closure, resulting in 
the rotation and opening of the TMDs to the extracellular space, and subsequent substrate 
translocation (Step II). The closed NBD dimer conformation is annulled as ATP hydrolysis 
commences, leading to conformational changes in the MSDs (Step III). The MSDs move 
into the open NBDs dimer conformation as ADP (adenosine diphosphate) and phosphate 
is released (Step IV). 
 
1.4 Multidrug resistance and Cancer 
Cancer is described as the abnormal and uncontrolled growth of cells. The United States 
recorded approximately 599,274 deaths due to cancer in 2018 [51]. Moreover, 18.1 million 
new cancer cases were recorded globally in the same year [52]. Although several cancer 
treatment options exist, one of the most effective treatment modalities for metabolic tumors 
is chemotherapy. Chemotherapy is a type of systemic treatment that involves the use of 
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drug formulations to target, control, and kill tumor cells [53]. Although oncology drug 
development has seen a paradigm shift from the low-budget, government-supported 
research effort to a high-stakes, multi-billion dollar industry [53], the challenge and 
limitations of chemotherapy experienced by early research still exist. One of the major 
challenges posed to the effectiveness and success of the chemotherapeutic regime is 
Multidrug Resistance (MDR). Multidrug resistance is described as a phenomenon in which 
tumor cells develop resistance to several drugs that may vary in both structure and mode 
of action [54]. Research has revealed that there are several mechanisms involved in the 
development of MDR. These include; cellular changes in cells that reduce the ability of the 
cytotoxic drug to kill cells such as changes in the cell cycle, elevated repair of DNA 
damage, decreased apoptosis occurrence, and altered drug metabolism, decreased uptake 
of water-soluble drugs including cisplatin and folate antagonists that need the service of 
transporters for cell entry, and increased energy-dependent efflux of hydrophobic drugs 
that can diffuse through the plasma membrane into the cell [55]. Studies have shown that 
the efflux of hydrophobic cytotoxic drugs by energy-dependent transporters like the ABC 
transporters is most common among the mentioned mechanisms. ABC transporters are 
major players in the absorption, excretion, metabolism, and elimination of drugs and their 
metabolites. For instance, ABC transporters like P-gp, MRP1, MRP2, and BCRP among 
others play pivotal roles in phase O and phase III of drug metabolism [5].  In phase O, these 
transporters are known to regulate the entry and extrusion of drugs before they reach their 
pharmacological target [5]. Moreover, ABC transporters are responsible for the complete 
elimination of metabolized molecules in phase III [5]. Transporters like P-gp have been 
associated with the transport of cationic drugs and their metabolites, whereas MRP2 and 
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BCRP are implicated in the transport of conjugate anionic drugs like conjugated 
glutathione across the plasma membrane [56]. The pharmacological aim of administering 
chemotherapeutic agents is to ensure the delivery of active compounds as much as possible 
to the molecular target in cancer cells to institute sufficient cellular damage to cause cell 
death. However, reduction in the intracellular drug accumulation has been reported to be 
one of the key factors that decrease the amount of active drug component that reaches these 
tumor cells [57]. Due to the essential role played by ABC transporters in drug metabolism, 
cancer cells in their intelligence overexpress these transporters as a means of protection 
against chemotherapeutic drugs and to ensure their survival.  This is accomplished as the 
overexpressed transporters cause substantial reductions in the intracellular concentration 
of the anticancer drugs resulting in reduced bioavailability and decreased pharmacological 
toxicity and potency in cancer patients. As such, MDR remains one of the major barriers 
to the effectiveness of chemotherapy and is reported to be responsible for a larger 
percentage (about 90%) of cancer related deaths. Thus there is the need for more critical 
and careful research  to be conducted into the role of ABC transporters in MDR. 
Although recent advancement in cancer research has explored the role of transporters like 
P-gp and BCRP in MDR to a greater extent, the role of transporters like MRP1 and MRP2 
are severely understudied. Recently, several retrospective analyses of chemotherapy results 
have reported high expression profiles of MRP1 and MRP2 [58, 59]. In addition, 
overexpression of MRP1 and MRP2 has been associated with higher incidence of treatment 
failure, resulting in cancer relapse and poor survival rates in some cancer patients [60, 61]. 
MRP1 is reported to confer resistance to anticancer drugs like methotrexate (MTX), 
anthracyclines (doxorubicin), etoposide, vincristine, paclitaxel, vinblastine among others 
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[41]. MRP2 also confers resistance to anticancer drugs like cisplatin, irinotecan, 
methotrexate, teniposide, mitoxantrone [46]. Aside from anticancer drugs, MRP1 and 
MRP2 also affect the bioavailability and efficacy of various antivirals, antimalarials, and 
antibiotics [19, 62]. The US food and drug administration recommendation in 2017 greatly 
encouraged the need to profile drug-transporter interactions for drugs in clinical trials with 
MDR transporter proteins like BRCP and P-gp [63]. But this recommendation excluded 
MRP1 and MRP2 although several studies have shown the effect of overexpression of 
MRP1 and MRP2 in MDR. Nonetheless, there is no specific recommendation for these 
transporters (MRP1 and MRP2) in the current FDA or EMA guidelines. Considering the 
essential role of MRP1 and MRP2 as well as their contribution to MDR, it is of great 
importance to explore the pharmacological essence and impact of these transporters by 
investigating their biochemical interactions with both new and promising drug targets.  
 
1.5 Role of modulators in chemotherapy 
The key role of ABC transporters in MDR cannot be overemphasized, as such finding ways 
of curbing the menace of ABC transporters in chemotherapy is of great importance to 
oncology research. Since ABC transporters are also essential for regulating cellular 
function and cellular balance, great consideration must be taken in considering the possible 
solutions in managing their role in MDR development. One approach that has been 
proposed by researchers is to completely shut down the efflux activity of these pumps. 
Although the aforementioned approach seems laudable since overexpression of the ABC 
transporter greatly hinders the bioavailability of the therapeutic drugs, this approach would 
be suicidal to the cells. This is because ABC transporters also play vital roles in tissue 
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defense and maintaining the physiological balance of cells. Thus, a complete shutdown of 
these transporters would mean a collapse in physiological stability and equilibrium. An 
alternate approach that provides a superior advantage is the modulation of the activity of 
ABC transporters in cancer patients through biochemical modulation. Biochemical 
modulation involves the modification of pathways and molecular targets by therapeutic 
agents to enhance the selective cytotoxic effect of anticancer drugs on tumor cells as well 
as to decrease their toxic side effects on normal cells [64, 65]. In clinical oncology research, 
biochemical modulation can also be described as a phenomenon in which the cytotoxicity 
of an active chemotherapeutic agent is modulated by one or several agents that may not 
have inherent cytotoxicity against a given normal or tumor cell population [66]. 
Modulation via this approach can result in the reduction of the cytotoxicity impact of the 
anticancer drug on normal tissues, and an elevation in the cytotoxicity effects of the 
anticancer agent on tumor cells. Furthermore, biochemical modulation can also be 
employed by using exogenously supplied metabolites to ensure selective manipulation of 
tumor cell metabolism to ensure the more selective response to the action of anticancer 
agents [67]. Several forms of biochemical modulation have been explored in oncology 
research and cancer therapy. This includes modulation to overcome drug resistance in drug-
resistant cells, modulation of the transport of anticancer agents, modulation of intracellular 
thiol levels to affect the extent of damage caused by radiation or chemical DNA damaging 
agents, increasing the sensitivity and exposure of tumor cells to chemotherapeutic agents 
by modulating the cytokine profile of tumor cells and normal cells [66]. With regards to 
overcoming MDR in refractory cancer cells, ligands that interact with ABC transporters 
can be grouped into substrates, inhibitors, activators, and inducers. Substrates are small 
17 
 
molecules or drugs that are effluxed by the transporters. Inhibitors are described as 
molecules that decrease or impair the activity of the transporter either by binding directly 
or indirectly to it. Inducers are molecules that enhance the expression levels of the 
transporter either by altering protein or gene expression levels. Activators are described as 
molecules that are reported to elevate the activity of the transporter. Activators exert their 
effect by binding to the transporter protein and cause a conformational change which 
provokes the transport of a substrate [68]. Via biochemical modulation, the activity of a 
specific transporter can be modulated without impacting the physiological steadiness of 
normal cells. Moreover, the biochemical modulation approach makes it possible to 
combine two or more pharmacological agents that may work by different molecular 
mechanisms at their respective effective doses without unacceptable side effects. As such, 
an anticancer drug that inhibit the activity of a specific transporter can be used together 
with a chemotherapeutic agent that is known to be a substrate of the transporter, yet has 
superior therapeutic potency against tumor cells. In this instance, the inhibitor can be used 
to decrease the efflux activity of the transporters, allowing the more potent anticancer drug 
to accumulate at the appropriate intracellular concentration and be bioavailable to elicit its 
effect. Thereby enhancing the effectiveness of combinatorial drug therapy. Combinatorial 
therapy is described as the use of two or more pharmacologic agents administered 
separately or in a fixed- dose as a single formulation.  
1.6 Current modulators of MRP1 and MRP2 
 MRP1 and MRP2 were discovered several years after the initial characterization of P-gp, 
yet there is little scientific information on modulators of MRP1 and MRP2 compared to 
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the diverse range of modulators for P-gp that have been well explored and characterized. 
Some current modulators of MRP1 and MRP2 are shown in table 1.3 
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Several decades of research have focused on overcoming MDR via pharmacological 
inhibition of ABC transporters like MRP1 and MRP2. However, there has been limited 
success due to high non-specific toxicity, low multidrug reversal effects, low potency, and 
undesirable off-target effects. Hence, contemporary clinical research strategies aim at 
identifying new selective modulators of ABC transporters that are more potent, well-
tolerated, and have limited non-specific toxicity. Moreover, taking a critical look at the 
modulators identified for P-gp, MRP1, and MRP2 in literature, it can be ascertained that 
the current knowledge base on MRP1 and MRP2 is still narrow. Thus, it is expedient for 
more research to be conducted to identify more potent modulators of MRP1 and MRP2 as 
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these transporters also play an essential role in MDR development. Interestingly, most 
research studies that aimed at identifying such modulators investigated the impact of these 
therapeutic agents on MRP1 and MRP2 activity but hardly examined their effect on protein 
or gene expression levels of MRP1 and MRP2. Thus it is needful to explore how such 
therapeutic agents may affect protein or gene expression levels since this may also reveal 
other molecular targets that may be of great therapeutic importance in our fight against 
MDR and cancer. 
 
1.7 Mechanisms for protein expression regulation 
Proteins represent one of the abundant macromolecules in living systems. This group of 
macromolecules has the most diverse range of functions across the various classes of 
macromolecules [84]. Proteins synthesis involves the conversion of information on the 
DNA (deoxyribonucleic acid) into messenger RNA (ribonucleic acid, mRNA) through a 
process called transcription. After which the information on the mRNA is then converted 
into a protein sequence via translation (Figure 1.3). The protein sequence then determines 
the protein folding, its conformation, biochemical role, stability, and half-life [84]. The 
protein expression levels for a specific protein of interest in the eukaryotic cell can be 








Figure 1.3 Protein synthesis illustrating transcription and translation steps 
[85] 
 
1.8 Transcriptional regulation  
Transcriptional control in the eukaryotic cell can be achieved by transcription factors (TFs) 
activation, TFs binding with specific DNA recognition sequences, and chromatin 
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remodeling [84]. TFs bind to their target site at once to form the transcription complex, 
thus they can regulate several genes disseminated in the genome [86]. TFs can be activated 
through small molecules that physically bind or allosterically alter the protein structure 
[84]. These small molecules act as modulators of protein expression and function by 
depending on specific transcription factors to exert their effect on their target [86].TFs can 
also be activated through cellular signaling pathways that create post-transcriptional 
protein modifications (PTMs). For instance, translation of the transcription factor, hypoxia-
inducible factor (HIF-1α and HIF-2α), can be elevated by signaling through the 
phosphatidylinositol 3 kinase (PI3K)/Protein kinase B (PKB/Akt) or the PI3K-Akt 
pathway [87]. The PI3-Akt signaling pathway also regulates a lot of downstream 
transcription factors like NF-kappa B (NF-kB) and activator protein 1 (AP-1) that play key 
roles in cell proliferation, cell survival among others in carcinogenesis [88]. TFs activation 
is greatly pleiotropic and has many cellular effects, as such several downstream target 
genes can be inactivated or activated based on the cell type and environmental conditions. 
TFs possess the capacity to rapidly and selectively find their target site. Thus they can bind 
to the target DNA site to either institute recruitment of the transcription machinery onto 
the promoter region of the gene of interest or hinder the recruitment of the transcriptional 
machinery [84]. This can either upregulate or suppress gene expression which in turn 
affects translation and protein synthesis.  
One way in which transcription can be regulated is via rearrangement of the chromatin 
structure. Chromatin consists of nucleosomes. Nucleosomes are described as DNA 
wrapped around a histone octamer. Modification to chromatin structure during 
transcription can be achieved by histone modifications, eviction or repositioning of 
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histones by histone chaperones, chromatin remodeling, and histone variant exchange [84]. 
Thus, Post-transcriptional modifications (PTMs) in the form of covalent modifications can 
be made on the histone tails by histone modifiers. The modifications alter the interaction 
and contact between histones and the DNA. Major modifications include acetylation and 
methylation of lysine residues. ATP-dependent chromatin remodelers can also use the 
energy from ATP hydrolysis to facilitate chromatin remodeling, which can be achieved 
through nucleosome sliding, nucleosome displacement, or incorporation and exchange of 
histone variants [89]. 
 
1.9 Translational regulation 
Translation describes the process of converting the information on the messenger RNA 
(mRNA) into a protein sequence. The integrity of protein synthesis must be greatly upheld 
to ensure minimal error during the process to warrant the synthesis of a functional protein. 
Ribosomes are the machinery that ensures the integrity of protein synthesis is upheld with 
great care.  It achieves this by matching the code from the template mRNA strand to the 
right amino acid. Due to the critical role the ribosomes play, the ribosome filter hypothesis 
by Mauro and Edelman in 2002 proposes that ribosomes function as translation 
determination factors [90]. As such, based on the specific ribosomal proteins and rRNA 
sequence in the ribosome complex, they filter and select for specific mRNA that should be 
translated. Thus, regulating the translation of these genes into proteins. Considering how 
the transcription and translation programs regulate protein expression, it can be seen that 
small-molecules if well-investigated and employed can offer the opportunity to modulate 
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protein expression levels through either of the aforementioned mechanisms. Hence this 
project seeks to provide a methodological alternative to the identification and 
characterization of modulators of MRP1 and MRP2 protein expression levels by screening 
various therapeutic agents from different drug libraries.  
1.10 In vitro assays to screen for modulators of ABC transporters 
Identification of interactions between new and promising drugs with ABC transporters is 
very essential for drug development. Studying drug-transporter interactions would provide 
essential information on how these transporters can impact drug disposition, efficacy, and 
toxicity. It would also create a pivotal platform to assist in the selection and optimization 
of new drug candidates. In vitro studies of ABC transporters and their interaction can be 
carried out via membrane-based assays or cell-based assays. Membrane-based assays 
involve the use of membranes made from cells expressing ABC transporters to study the 
efflux function of these transporters [75]. Membrane-based assays include membrane 
vesicular transport assays, ATPase assays, and photoaffinity labeling assays [69]. Cell-
based assays, on the other hand, are performed using intact cells, such assays include; 
protein determination assays (In-cell ELISA, western blot), flow cytometry assays, 
cytotoxicity assays among others.  
 
1.10.1 In-Cell ELISA assay (ICE) 
One of the valuable assays for rapidly characterizing a wide range of cell signaling 
parameters in the development of targeted therapeutics is the In-Cell ELISA assay (ICE). 
ICE is also known as In-cell western assay, Cell-based ELISA, Cytoblot, or FACE (Fast 
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Activated cell-based ELISA). It is cell-based immunocytochemistry that allows the 
quantification of target proteins or post-translational modifications of target proteins in 
cultured cells (adherent and non-adherent cells). This assay is based on the principle that 
using target-specific antibodies, proteins can be detected in fixed and permeabilized 
cultured cells. Moreover, the ICE assay bypasses the protein harvesting, lysate preparation, 
electrophoretic separation, and electrophoretic transfer steps of western blot.  Thus, it 
provides a simple and rapid platform for immunodetection of target proteins using 
antibodies. Since this assay requires no protein separation, the primary antibodies used 
must be highly specific for the protein of interest.  This technique also demands the 
segregation of signals due to the protein of interest from the normalization signal due to a 
reference protein (Actin, Tubulin, Glyceraldehyde -3 – phosphate – dehydrogenase 
(GAPDH) into two detection channels [91]. To achieve greater precision, normalization 
can be done to correct for well-to-well variation in cell numbers. This can be achieved by 
normalizing signals from the protein of interest to an internal control protein/ reference 
protein or cell using a cell tag staining (example Cell tag 700) or cell labeling with a 
reactive dye. In addition to being simple and rapid, ICE has the added advantage of 
amalgamating the specificity of western blot and the replicability and high throughput of 
ELISA. As such it can be performed in either 96 or 384 well-formatted plates.  Studies 
have also shown that ICE yields similar results to western blot whilst providing superior 
replicability and precision [91, 92]. Due to its flexibility and high throughput nature, it can 
be used for various screening purposes. In this project, ICE was adapted as the major high-




1.10.2 Western blot assay 
Changes in the protein expression levels of cells after stimulation can be determined using 
traditional western blot. It is one of the common assays used in the detection and 
quantification of proteins in biomedical research [93]. In this immunodetection technique, 
proteins are first separated and then identified using target-specific antibodies [94]. The 
procedure involves the preparation of whole cell lysate from harvested cells and the 
separation of proteins based on their molecular weight. The separation of proteins in the 
whole cell lysate can be achieved by conducting electrophoresis. The proteins are then 
transferred unto a membrane (normally a nitrocellulose or polyvinylidene difluoride 
(PDVF)) and exposed to labeled target-specific antibodies [94]. The membrane is then 
washed to get rid of unbound antibodies. Antibodies that bind to the protein of interest give 
rise to a signal band that is specific for the protein of interest. This band can be detected 
using a chemiluminescent or fluorescent substrate. The signal can then be developed as a 
film or detected using a camera-based detection. Although the film detection technique is 
reported to be robust and sensitive, its dynamic range of quantification is poor compared 
to the camera-based detection which offers superior sensitivity and excellent quantification 
range [95]. In the western blot assay, the amount of protein present in the sample is 
representative of the intensity and thickness of the signal band that is visualized. To cater 
for differences in the electrophoresis loading, detection of housekeeping protein like; 
tubulin, actin, and GAPDH is performed [96]. Normalization of target signals can be done 
using reference signals obtained either from housekeeping proteins (HKPs) after 
immunochemical staining or using the total protein  (TP) intensity on blotting membranes 
after total protein staining [93]. Advantages of this assay include the fact that, it is sensitive 
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and the same protein transfer blot can be used for a different analysis of multiple proteins 
[75]. However, due to the several processing steps in the western blot assay, it is known to 
be a low-throughput and labor-intensive technique [91].  
 
1.10.3 Fluorescence accumulation assays using flow cytometry analysis 
The impact of a therapeutic agent on the activity of an ABC transporter can be assessed by 
measuring the intracellular accumulation of a fluorescent substrate in cells that overexpress 
the ABC transporter of interest, in the presence or absence of a test compound. As such, 
fluorescence accumulation assays are one of the tools that have gained popularity in 
understanding how various test compounds/drugs can impact the functional activity of 
ABC transporters. It is based on the analogy that, there would be a low accumulation of 
fluorescent substrate in non-treated cells that overexpress ABC transporters like MRP1, P-
gp, and MRP2 among others. This is because the fluorescent substrate is effluxed out of 
the intracellular space by the transporter resulting in low fluorescence. However, in the 
presence of an inhibitor of the transporter, there would be a high accumulation of the 
fluorescent substrate.  This is because the inhibitor dampens/decreases the efflux activity 
of the transporter, thus leading to an increase in the intracellular fluorescence 
accumulation. Low intracellular fluorescence accumulation can also be observed in the 
presence of inducers or activators. Since activators only induce conformational changes, 
they require less incubation time in eliciting their effect, inducers on the other hand would 
require de novo synthesis of the transporter thus they need extended incubation time to 
elicit their effect [97]. In most studies, detection using fluorescent substrate is preferred 
over radioactive and analytical tools like mass spectrometry because it provides superior 
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sensitivity, greater convenience, and lower cost [98]. Visualization of a fluorescent 
substrate can be achieved using a fluorescence microscope, however, this method does not 
give a quantitative measurement of parameters. A spectrophotometer with fluorescence 
abilities can also be used but this approach is also limited by its low sensitivity [98]. One 
method that is reported to offer greater sensitivity whilst allowing quantitative 
measurement of intracellular accumulation of fluorescent substrates is flow cytometry [99-
101].  Flow cytometry involves the use of fluorescent dyes and fluorescent antibodies that 
can bind to specific cellular components such as proteins on cell membranes or cell surface 
molecules among others. It is based on the principle that fluorescently labelled cells when 
passed through a light source get excited to a higher energy state. On returning to the 
ground/rest state, the fluorochromes emit light energy at higher wavelengths. The 
fluorescence emitted is collected by the flow cytometer, spectrally filtered and detected 
using a photomultiplier tube [102]. Thus, this technique allows quantitative measurement 
of single cells/particles or cellular constituents at high-speed rates [82]. Since test 
compounds that emit inherent fluorescence at emission wavelengths similar or close to the 
fluorescent substrate can interfere with quantification, it is needful to consider the 
background fluorescence of the compounds of interest during quantification. Flow 
cytometry can be used to measure the fluorescence and optical characteristics relevant for 
the studying of mammalian cells, as such it has become an essential tool for studying the 
regulation and interaction of cell systems [75]. Recent advancement in flow cytometry 
assays has also paved the way for the use of multiple fluorochromes that emit light at 
specific and varying wavelengths but share similar excitation wavelengths. This has 
created a platform that enables the measurement of different cell properties concurrently 
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[102]. Hence, in the study of ABC transporters, flow cytometry has been commonly 
employed in understanding and characterization of the interaction between therapeutic 
agents and ABC transporters. Commonly used fluorescent substrates include calcein 
acetoxymethyl ester (Calcein-AM) and rhodamine 123, with Calcein-AM being the ideal 
reference fluorescent substrate for P-gp and MRP1 studies [103].  
 
1.11 The rationale of the study 
There is no doubt that the discovery of modulators of ABC transporters has had several 
potential therapeutic benefits especially for patients with drug-resistant tumors. Even 
though most identified modulators of ABC transporters had significant effects on 
regulating its transport activity, one of the key challenges encountered in clinical trials has 
been the efficacy and safety of these modulators. Some dreadful side effects and elevated 
levels of patient toxicities have been reported due to adverse pharmacokinetic interactions 
with administered anticancer drugs. For instance, the coadministration of cyclosporin A 
and etoposide to a patient with acute T-lymphocytic leukemia in relapse resulted in 
progressive hyperbilirubinemia and mental confusion [104]. Therefore, there is a need for 
more potent, low toxic, and well-tolerated drugs. Moreover, a critical review of literature 
on modulators of ABC transporters like MRP1 reveals that although most MRP1 
modulators could influence transporter activity, little is known about their impact on the 
gene and protein expression levels of these transporters. Thus, further research must be 
conducted to investigate how current and future therapeutic agents that interact with ABC 
transporters may affect their protein and gene expression levels. This would provide 
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essential data on drug-transporter interactions, which is important for clinical trials. 
Moreover, therapeutic agents that show the ability to decrease protein expression could be 
used together with drugs that are known to be efficacious in treating cancer but are 
unfortunately substrates of these transporters. Thus in the presence of the drug that 
decreases protein expression of the transporter, the more potent drug would have higher 
bioavailability to exert its effect on the cancer cells, thereby enhancing combinatorial drug 
therapy. Identification of modulators of ABC transporters like MRP1 and MRP2 would 
also enable the scientific community and the pharmaceutical industry to gain greater insight 
into the causes of treatment failure and relapses experienced by cancer patients, as well as 
provide a possible therapeutic approach to enhance effectiveness of chemotherapy. Aside 
from cancer treatment, findings from such studies would provide great enlightenment for 
the treatment of other diseases in which these transporters are implicated whilst deepening 
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Novel ATP competitive inhibitors downregulate Multidrug resistance protein 1 
(MRP1) expression in MRP1- overexpressing cells 
Abstract 
Multidrug resistance protein 1 (MRP1) is an integral membrane protein that serves as an 
ATP-dependent drug efflux pump. It plays a pivotal role in the efflux of a wide variety of 
endogenous and exogenous substrates such as toxic chemicals, drugs, and their metabolites 
out of cells.  Overexpression of MRP1 confers resistance against commonly used 
chemotherapeutic agents in tumor cells. In chemotherapy, the emergence of the 
combinatorial therapeutic approach led to a major improvement in survival rates of several 
cancers, however multidrug resistance (MDR) has been a major challenge to its 
effectiveness. Thus it is of great clinical interest to identify compounds which can modulate 
MRP1 expression and activity without perturbing physiological homeostasis. Using an In-
Cell ELISA assay we screened 30 drugs which consisted of both clinically tested anticancer 
drugs and recently approved FDA drugs to investigate their effect on MRP1 expression. 
We identified a total of 7 modulators, of which 4 test compounds increased the protein 
expression levels of MRP1 whereas 3 test compounds decreased the protein expression of 
MRP1. Four of the modulators identified (Amuvatinib, SB743921 HCl, TG101348 
(SAR302503), Felbamate) have never been reported as modulators of MRP1, thus these 
compounds were selected for further characterization in this study. Three of the novel 
modulators of MRP1 discovered (Amuvatinib, SB743921 HCl, and TG101348 
(SAR302503)) decreased MRP1 protein expression and were identified to be ATP 
47 
 
competitive inhibitors based on their mode of action. Felbamate (recently approved FDA 
drug) increased MRP1 protein expression. Further characterization of our novel 
modulators using In-Cell ELISA assay showed that SB743921 HCl and Amuvatinib 
decreased MRP1 protein expression in a concentration and time-dependent manner. 
Calcein AM accumulation assay performed to ascertain the impact of the selected hit 
compounds on MRP1 efflux activity revealed that TG101348 (SAR302503), Amuvatinib, 
and SB743921 HCl decreased MRP1 efflux activity. Cell viability and reversal of MRP1-
mediated resistance to vincristine studies carried out using MTT assay also showed that 
TG101348(SAR302503) and Amuvatinib were more potent at reversing MRP1-mediated 
resistance. The discovery of key and novel modulators of MRP1 is a step in the right 
direction to aid revert MDR in cancer patients. Findings from this project would provide 
essential information to improve combinatorial drug therapy and precision medicine as 
well as reduce drug toxicity of various cancer chemotherapies.  
 
Keywords: ABC transporters; multidrug resistance; MRP1; ABCC1; MRP1 modulators; 
In-Cell ELISA; protein expression;  anticancer drug; FDA approved drug; drug profiling;  
drug-transporter interactions 
1) SB743921 HCl (PubChem CID: 49867937); 2) Amuvatinib (PubChem CID: 
11282283); 3) TG101348 (SAR302503) (PubChem CID: 16722836); 4) Felbamate 




Cancer is the second leading cause of mortality and morbidity globally. In 2018, 
approximately 18.1 million new cancer cases, and an estimated 9.6 million cancer-related 
deaths were recorded worldwide [1]. Although several treatment modalities exist for cancer 
therapy, chemotherapy remains the standard treatment method for various types of cancers. 
Chemotherapy is described as the use of drug formulations to target, control, and kill tumor 
cells in a systemic treatment module [2]. Even though chemotherapy has been successful 
and beneficial in cancer therapy, the challenge of multidrug resistance (MDR) limits its 
effectiveness. MDR is a phenomenon in which cells develop resistance to several drugs 
that may differ in structure, molecular target, and mode of action [3]. Studies into the 
development of MDR revealed several mechanisms that are implicated in this 
phenomenon. These mechanisms include; cellular changes in cells that minimize the ability 
of cytotoxic drugs to kill cells such as elevated repair of DNA damage and evasion of 
apoptosis among others. The other mechanisms reported include decreased uptake of 
water-soluble drugs (folate antagonists and cisplatin) that utilize transporter proteins for 
cell entry and increased energy-dependent efflux of hydrophobic drugs through the plasma 
membrane of cells [3]. One superfamily of transporters whose overexpression has been 
implicated in MDR is the ATP-Binding Cassette superfamily of transporters (ABC 
transporters). ABC transporters represent a diverse and ubiquitous superfamily of 
transporters that utilize ATP hydrolysis for their transport activities [4]. This group of 
transporters is known to facilitate the transport of a variety of molecules ranging from small 
molecules to highly charged and hydrophobic molecules including peptides, vitamins, 
toxins, drugs, and their metabolites across biological membranes [5].   
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ABC transporters are present in every phylum of life. Based on their direction of transport 
relative to the cytoplasm, they can be categorized into importers and exporters [6]. In 
prokaryotes, this group of transporters can function as importers or exporters, however, 
they function solely as exporters in eukaryotes.  A total of 49 ABC transporters have been 
identified in the human genome. These transporters have been classified into seven 
subfamilies (A-G) based on their protein domain and amino acid sequence [7, 8]. ABC 
transporters like P-glycoprotein (P-gp), Multidrug resistance protein 1 (MRP1), and Breast 
cancer resistance protein (BCRP) have been reported to play pivotal roles in the absorption, 
excretion, metabolism, and elimination of drug and their metabolites [6]. In phase O and 
phase III of drug metabolism, these transporters regulate the entry and extrusion of drugs 
before reaching their pharmacological target as well as ensure the complete elimination of 
metabolized molecules [6]. As major players in drug metabolism, the overexpression of 
some ABC transporters have been implicated in reduced intracellular accumulation and 
therapeutic potency in anticancer drugs in cancer patients [9]. The prototypical ABC 
transporter is characterized by a transport core consisting of four main domains; two sets 
of membrane-spanning domains (MSDs) and two sets of cytosolic nucleotide-binding 
domains (NBDs) [10]. The MSD comprises six transmembrane α-helices that form the 
substrate-binding site/s and facilitate substrate translocation across the plasma membrane 
[11]. The NBDs on the other hand consists of the Walker motifs (Walker A and Walker B) 
that bind to ATP for ATP hydrolysis [12]. Upon ATP binding and hydrolysis, the NBDs 
dimerize to cause conformational changes that result in the rearrangement of the MSDs to 
an outward-facing conformational and subsequent efflux of the substrate. MRPs in the 
ABCC subfamilies possess an extra NH2-proximal membrane-spanning domain known as 
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the MSD0 [13]. The MSD0 is reported to aid the trafficking, retention and recycling of the 
transporter to the plasma membrane [14].  
MRP1 is a 190-kDa ATP-dependent efflux transporter [15]. It is expressed in the lungs, 
kidney, small intestines, and at pharmacological sanctuary sites including the blood-brain 
barrier, blood-testis barrier, and the blood placenta barrier [15-18]. MRP1 localizes at the 
plasma membrane and governs the absorption and deposition of a broad spectrum of 
substrates [19]. Substrates of MRP1 include heavy metals, toxins, drugs, and metabolites 
[20, 21]. The pharmacological aim of administering an anticancer drug is to ensure the 
maximum delivery of its active component to the desired therapeutic target in tumor cells, 
to initiate enough cellular destruction to cause cell death [9]. However, the overexpression 
of ABC transporters like MRP1 facilitates the efflux of such administered anticancer drugs 
leading to decreased bioavailability and therapeutic potency of these drugs. As such, 
overexpression of MRP1 has been implicated in MDR of many carcinomas and has been 
reported to be associated with the elevated risk of treatment failure leading to cancer relapse 
and low survival rates among cancer patients [22]. In addition to conferring resistance to 
anticancer drugs like paclitaxel, etoposide, and doxorubicin, MRP1 also affects the 
bioavailability and efficacy of antivirals, antimalarials, antibiotics [23]. Aside the critical 
role MRP1 plays in MDR, it also aids in maintaining physiological homeostasis by 
regulating redox homeostasis, steroid metabolism among others [24]. MRP1 also acts as a 
key player in the etiology of neurodegenerative diseases like Alzheimer's disease and 
cardiovascular diseases [24].  
Biochemical modulation plays a key role in chemotherapy. It is described as the process in 
which pathways or molecular targets are biochemically modified by therapeutic agents to 
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enhance the selective cytotoxic effect of anticancer agents on cancer cells but decrease their 
toxic side effects on normal cells [25, 26]. Biochemical modulation offers a means of 
regulating the activity of ABC transporters like MRP1 without perturbing the physiological 
balance in normal cells. Moreover, modulators also have the added advantage of boosting 
oral availability and enhancing the penetration of drugs that are transported by MRP1 in 
tissues [27]. In this present study, we screened 30 drugs consisting of both anticancer and 
recently approved FDA drugs to ascertain their effect on MRP1 protein expression levels 
using In-Cell Enzyme-Linked Immunosorbent assay (In-Cell ELISA) assay. We identified 
4 novel drugs that modulated MRP1 protein expression in MRP1-overexpressing cells. 
These drugs included 3 novel ATP competitive inhibitors that down-regulated MRP1 
protein expression and one FDA approved drug that increased MRP1 protein expression. 
The ability of test compounds to modulate MRP1 activity and reverse MRP1-mediated 




2.0 Materials and methods 
2.1 Chemicals  
Test compounds consisting of anticancer and FDA approved drugs were procured from 
Selleck Chemicals (Houston, TX), and APExBIO Technology LLC (Houston, TX). 
MK571 was acquired from APExBIO Technology LLC (Houston, TX), thiazolyl blue 
tetrazolium bromide (MTT) was procured from Sigma-Aldrich (St. Louis, MO) and 
Calcein acetoxymethyl ester (Calcein AM) was obtained from Corning Life Sciences 
(Corning, NY). 
 
2.2 Cell lines and cell culture 
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD). Dulbecco’s modified Eagle medium (DMEM) (GE 
Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine serum (FBS) 
was used to grow the HEK293 cell lines. Cell lines were cultured in a humidified incubator 
maintained at 5% CO2 at 37 °C. This incubation condition was retained in all subsequent 
cell culture procedures. 
 
2.3 Screening of compounds using  In-Cell ELISA  assay  
In-Cell ELISA assay was used to screen the test compounds for modulators of MRP1 
protein expression. HEK293/pcDNA3.1 and HEK293/MPR1 cells were seeded at a cell 
density of 5 x 104 cells per well in 96-well plates with DMEM containing 10% FBS, treated 
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with drugs (10 uM), and 0.1% DMSO (controls) after 24 hours, Cells were incubated for 
48 hours after drug treatment at 37 °C. At the end of the incubation period, treatments were 
removed and cells were rinsed twice with 150 μl of PBS. Cells were fixed with 3.7% 
paraformaldehyde and permeabilized with Triton X-100. The cells were blocked using fish 
gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal anti-
MRP1 antibody (1:500; IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin 
antibody (1:1000; T5168, Sigma -Aldrich) used as the internal control. Horseradish 
peroxidase-conjugated goat anti-mouse secondary antibody (Thermo Fisher Scientific) was 
incubated for an hour at room temperature. Target proteins were detected with 
chemiluminescence using Super signal West Dura® Extended Duration Substrate 
(21EAPI34076, Thermo Fisher Scientific) and read using Hidex Sense Beta Plus plate 
reader (Turku, Finland). Experiments were conducted in two independent studies, with 
treatments performed in duplicates.  
 
2.4 Determination of the concentration-dependent activity of selected hit compounds 
on MRP1 protein levels using  In-Cell ELISA  assay  
HEK293 MRP1 overexpressing cells and HEK293/pcDNA3.1 cells were seeded in 96-well 
plates as described earlier. Cells were treated with varying concentration of test 
compounds;1 µM, 5 µM, 10 µM, 20 µM and incubated at 37 °C for 48 hours. Final DMSO 
concentration was maintained at less than 0.2% (v/v). Cells were fixed, permeabilized, and 
blocked as detailed earlier. Incubation with monoclonal anti-MRP1 antibody (1:250; 
IU5C1, MA516079, Thermo Fisher Scientific) and anti-α tubulin antibody (1:1000, T5168, 
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Sigma-Aldrich) was conducted overnight at 4 °C. Horseradish peroxidase-conjugated goat 
anti-mouse secondary antibody incubation was performed for an hour at room temperature. 
Target proteins were detected using western blotting luminol reagent (Santa Cruz 
Biotechnology, sc-2048), and read using Hidex Sense Beta Plus plate reader (Turku, 
Finland). Treatments were done in triplicates. 
 
2.5 Time-dependent activity of selected hit compounds on MRP1 Protein levels using  
In-Cell ELISA assay. 
HEK293/MRP1 and HEK293/pcDNA3.1 cells were seeded as detailed above and treated 
with 10µM of test compounds and incubated for various time points; 12, 24, and 48 hours 
at 37°C. Controls were treated with 0.1% DMSO. Cells were fixed, permeabilized, and 
blocked as indicated earlier. After which, cells were incubated with monoclonal anti-MRP1 
antibody (1:250; IU5C1, MA516079, Thermo Fisher Scientific) and anti-α tubulin 
antibody (1:1000, T5168, Sigma-Aldrich) was conducted overnight at 4 °C. Followed by 
incubation with horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) for an hour 
at room temperature. Western blotting luminol reagent (Santa Cruz Biotechnology, sc-
2048) was used for detection of target proteins, and plates were read using Hidex Sense 
Beta Plus plate reader (Turku, Finland). Treatments were performed in triplicates. 
 
2.6 Flow cytometric measurements  of  intracellular Calcein accumulation  
Flow cytometry was conducted to determine the effect of selected drugs on MRP1 
mediated efflux of calcein-AM. Calcein-AM was used as the fluorescent substrate for the 
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accumulation assay, with MK571 as the positive control. HEK293/MRP1 cells were 
prepared in serum-free medium at a cell density of 7×105 cells/ml and treated with test 
compounds (10μM final concentration), MK571 (25 μM final concentration), and DMSO 
(0.1% final concentration for controls). Cells were incubated at 37 ⁰C for 10 minutes. After 
incubation, the cells were treated with Calcein-AM (0.25 µM)  and incubated for additional 
30 minutes. Ice-cold PBS buffer (3 ml) was added to halt the reaction, after which cells 
were centrifuged and washed twice with cold PBS. Cells were then resuspended in a cold 
PBS buffer containing 1% paraformaldehyde. Detection of intracellular accumulation of 
calcein-AM was done using a BD Accuri C6 flow cytometer ( BD Biosciences, San Jose, 
CA) with excitation at 480 nm, and emission and 533/30 nm. Fluorescence intensities are 
representative of the mean value collected from 10,000 events.  Treatments were done in 
duplicates and conducted in three independent experiments. 
 
2.7 Cytotoxicity of selected test compounds 
The sensitivity of HEK293/MRP1 and HEK293/ pcDNA3.1 cells towards the selected test 
compounds were determined using the MTT colorimetric assay. Cells were seeded at a cell 
density of 5 × 103 per 100 ul of culture medium in 96 well plates. After 24 hours, cells were 
treated with 100ul of test compounds at varying concentrations. The final DMSO 
concentration was kept at 0.05%. Cells were then incubated for 72 hours, after which 100 
ul of the spent culture medium was carefully removed. Cells were then treated with MTT 
(0.5 mg/ml) for 4 hours. The formazan crystals were dissolved by the addition of 100 ul of 
15% SDS containing 10 mM HCl and absorbance at 570 nm was recorded using a Hidex 
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Sense Beta Plus plate reader (Turku, Finland). Treatments were done in triplicates, and 
experiments were performed in two independent studies. 
 
2.8 Resistance reversal assay 
The ability of test compounds to reverse MRP1 mediated resistance towards the 
chemotherapeutic drug, vincristine was analyzed using the MTT colorimetric assay. Cells 
were seeded in 96 well plates at a cell density of 5 × 103  per 100 ul of culture medium. 
After 24 hours, cells were treated with 50 ul of test compounds at selected concentrations 
prepared in a culture medium. After an hour, 50 ul of vincristine at varying concentrations 
was added to the cells. Final DMSO was maintained at 0.2%, and cells were incubated for 
72 hours. At the end of the incubation period, 100 ul of the spent culture medium was 
carefully removed. Cells were treated with MTT (0.5 mg/ml) for 4 hours. The formazan 
crystals were dissolved by the addition of 100 ul of 15% SDS containing 10 mM HCl and 
absorbance at 570 nm was recorded using a Hidex Sense Beta Plus plate reader (Turku, 
Finland). Treatments were done in triplicates, and experiments were performed in two 
independent studies.  
 
2.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism TM software (GraphPad 
Software version 8.4.3, San Diego, CA, USA). The differences between mean values were 
analyzed using linear mixed model analysis. Sidak correction was applied for multiple 




3.1 Screening for modulators of MRP1 protein expression using In-Cell ELISA assay 
In-Cell ELISA also known as In-cell western assay or Cytoblot is a cell-based 
immunocytochemistry assay that allows quantification of target proteins in cultured cells. 
It merges the specificity of western blot, the replicability, and the high-throughput nature 
of ELISA. To identify modulators of MRP1 protein expression levels, we screened 30 
drugs (consisting of both clinically tested anticancer and recently approved FDA drugs) 
using In-Cell ELISA assay in HEK293 MRP1-overexpressing cells. The MRP1 protein 
expression in HEK293/MRP1 treated with 0.1% DMSO was considered as the baseline for 
computing the percent modulation for the test compounds. The screening was conducted 
in 96-well format in two independent studies. The percent modulation of MRP1 protein 
expression by the test compounds from the two independent studies is represented in Figure 
2.1. A test compound was considered as a “Hit compound” if its calculated percent 
modulation is ≥ 30% in the positive (+) or negative (-) direction. Test compounds that 
showed percent modulation ≥ 30% are presented as red dots in Figure 2.1, whereas drugs 
that showed percent modulation < 30% are represented by black dots. The screening 
process identified a total of 11 hit compounds that modulated the protein expression of 
MRP1 ≥ 30%. The identified hit compounds, their therapeutic targets, and specific percent 





Figure 2. 1. Screening of compounds using In-Cell ELISA assay. 
 HEK293/MRP1 cells were treated with 10 µM of test compounds and incubated for 48 
hours. MRP1 protein expression was detected using a monoclonal anti-MRP1 antibody 
(1:500; IU5C1, MA516079, Thermo Fisher Scientific). Alpha-tubulin protein (used as an 
internal control) was detected using mAb α-tubulin (1: 1000; T5168, Sigma – Aldrich). 
Secondary antibody; mAb-goat-anti-mouse (1:1000) was used. Treatments were 
performed in duplicates and experiments were conducted in two independent studies. Red 
dots represent drugs that showed ≥ 30% modulation of   MRP1  protein expression. Black 





Table 2.1 Modulatory effect of drugs on MRP1 protein expression 
 
Compound Target % Modulation on MRP1 












Trichostatin A (TSA) 
LY294002 
































Na+-K+-Cl- cotransporter  
HSP  
NMDA receptor 
-2.88 ± 0.08 
-12.23 ± 0.14 
0.47 ± 0.16 
-40.80 ± 0.09 
5.17 ± 0.09 
13.88 ± 0.04 
-12.09 ± 0.12 
-50.70 ± 0.01 
75.19 ± 0.07 
-25.00 ± 0.10 
-12.67 ± 0.06 
21.04 ± 0.05 
-27.38 ± 0.02 
-18.15 ± 0.07 
-44.22 ± 0.1 
-7.239 ± 0.11 
-56.79 ± 0.12 
-60.30 ± 0.05 
76.98 ± 0.09 
20.85 ± 0.12 
-10.51 ± 0.02 
-20.25 ± 0.09 
93.54 ± 0.20 
a 
Mean ± SEM of n ≥ 2 independent experiments.  
* Hit compounds – showed ≥ 30% modulation 
***Hit compounds characterized – showed ≥ 50% modulation 
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Table 2.1 (Continued) Modulatory effect of drugs on MRP1 protein expression 
a Mean ± SEM of n ≥ 2 independent experiments.  
* Hit compounds –showed ≥ 30% modulation 
***Hit compounds characterized – showed ≥ 50% modulation 
 
Out of the 11 hits identified, 5 test compounds increased the protein expression levels of 
MRP1 and 6 test compounds decreased the protein expression of MRP1. For detailed 
characterization, hit compounds that modulated protein expression of MRP1 ≥ 50% were 
considered. Seven of the hit compounds showed modulation of MRP1 protein expression 
≥ 50%. Among these hits, three compounds (Vismodegib, Epirubicin HCl, and Irinotecan) 
have already been reported to modulate MRP1 in other studies [28-30]. Thus, these 
compounds were not further characterized. In this study, we focused on characterizing the 
other 4 novel test compounds that to the best of our knowledge have not been reported for 
their activity as modulators of MRP1 protein expression (Table 2.2). This included 3 ATP 
competitive inhibitors; SB743921 HCl, Amuvatinib, TG101348 (SAR302503), and an 
FDA approved drug, Felbamate. SB743921 HCl, Amuvatinib, and TG101348 
(SAR302503) decreased MRP1 protein expression levels by 60.30%, 50.70%, and 55.11% 
Compound Target % Modulation on MRP1 


















-0.97 ± 0.02 
-4.50 ± 0.06 
41.90 ± 0.03 
13.84 ± 0.04 
34.03 ± 0.04 
-55.11 ± 0.06 
24.68 ± 0.01 
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respectively, with  SB743921 HCl eliciting the highest negative modulation of MRP1 
protein levels. Felbamate on the other hand increased MRP1 protein expression levels by 
93.54 % in the HEK293 overexpressing MRP1 cells. The chemical structures of the 
selected compounds are shown in Figure 2.2.  
 
Table 2.2 Chemotherapeutic targets, % modulation of MRP1 protein expression for 
selected and characterized Hit compounds 
Compound Chemotherapeutic 
targets 




Effect on MRP1  
protein levels 
SB743921 HCl  Kinesin 
  
60.30 ± 0.05 Decrease 
Amuvatinib 
  





55.11 ± 0.06 Decrease 
Felbamate N-Methyl-D-aspartate 
(NMDA) receptor 















3.2 Concentration and time-dependent activity of selected hit compounds for MRP1 
In order to determine if the modulatory effects observed for our selected compounds were 
concentration and time-dependent and to identify the conditions that produce the maximum 
modulatory effect, we conducted concentration and time-dependent studies using the In-
Cell ELISA assay. HEK293 MRP1 overexpressing cells were treated with varying 
concentration (1  µM, 5 µM, 10 µM, 20 µM) of the test compounds for the concentration-
dependent studies. In the time-dependent studies, cells were treated with 10 µM of test 
compounds, and were incubated at various time points; 12 hours, 24 hours, and 48 hours. 
As shown in Figure 2.3A; expression levels of MRP1 were further reduced by increasing 
concentrations of SB743921 HCl and Amuvatinib. Drug treatment of 20 µM exhibited 
strongest modulatory effect and resulted in 75.62 % and 85.28% reduction in MRP1 
expression by SB743921 HCl and Amuvatinib, respectively. TG101348 (SAR302503) 
showed highest downregulation of MRP1 protein expression at 10 µM. Treatment with 
Felbamate also showed concentration dependence and highest modulatory effect on MRP1 
expression levels was observed in case of 10 µM drug treatment. Regarding time-
dependence studies, as presented in Figure 2.3B, all drug treatments demonstrated time-
dependence and the highest modulatory effect was observed with 48 hour treatment. 
Therefore, in case of  SB743921 HCl, Amuvatinib and TG101348, MRP1 expression levels 
were reduced by 62.83%, 49.29% and 49.28% respectively by 48 hour drug treatment. In 





Figure 2.3 Concentration and time-dependent activity of selected hit compounds on MRP1 protein 
expression using In-Cell ELISA assay. 
[A] Concentration dependent activity of test compounds on MRP1 protein expression; HEK293/MRP1 
cells were treated with 1 µM, 5 µM, 10 µM and 20 µM of test compounds and incubated for 48 hours. [B] 
Time dependent activity of selected hit compounds on MRP1 protein expression, HEK293/MRP1 cells 
were treated with 10 µM of test compounds and incubated for 12, 24, 48 hours. Treatments were performed 
in triplicates and data analyzed using linear mixed model and Sidak post hoc test. Data is represented as 





























































































3.3 Effect of test compounds on MRP1 efflux activity using calcein accumulation assay  
Overexpression of MRP1 has been associated with the increased efflux of multiple classes 
of therapeutic agents across biological membranes. This results in the low bioavailability 
and reduced pharmacological potency of such compounds. We investigated the effect of 
the selected compounds on MRP1 efflux activity of calcein-AM using a flow cytometry-
based assay. Calcein-AM is a well-known substrate of MRP1. This non-fluorescent 
compound is converted into a highly fluorescent molecule when its acetoxymethyl ester 
(AM) component is cleaved off by cellular esterases. Using flow cytometry, the 
intracellular calcein fluorescence accumulation can be ascertained. In this assay, 
HEK293/MRP1 cells were treated with 10 µM of the test compounds for 10 minutes before 
the treatment with calcein-AM was conducted for an extra 30 minutes. Our results as 
presented in Figure 2.4 shows that 25 µM of MK571 (commonly used MRP1 inhibitor) 
increased intracellular calcein-AM by 3.85-fold compared to the no treatment control. 
Among the selected compounds; SB743921 HCl, Amuvatinib, and TG101348 
(SAR302503) significantly increased the calcein accumulation by 3.51-fold, 1.75-fold, and 
2.52-fold respectively with  SB743921 HCl exhibiting highest modulatory effect on MRP1 
activity compared to no treatment control. Felbamate, on the other hand, did not have any 






Figure 2.4 Effect of selected hit compounds on MRP1 mediated calcein efflux.  
HEK293/MRP1 cells were treated with 10 µM of the test compounds, and 25 µM of 
MK571 (positive control) for 10 minutes at 37°C before treatment with 0.25 µM calcein-
AM for 30 minutes. Flow cytometric measurements of intracellular calcein-AM was 
conducted at 488 nm and 533/30 nm for excitation and emission wavelengths, respectively. 
Experiments were done as duplicates in three independent experiments and presented as 
mean ± S.E.M. Data was analyzed using a linear mixed model and Sidak post hoc test. *P 









































































3.4 In vitro cytotoxicity of selected test compounds 
The half-maximal inhibitory concentration (IC50) is a measure of the effectiveness of a 
specific compound to inhibit a specific biochemical or biological function. Results from 
the cytotoxicity studies using MTT as shown in table 2.3, reveals that Amuvatinib was the 
most potent in inhibiting the growth of HEK293/MRP1 cells with an average IC50 of 2.64 
µM. TG101348 (SAR302503) with an average IC50 of 3.26 µM was also very potent in 
inhibiting the growth of HEK293/MRP1 cells. SB743921 also showed an inhibitory effect 
on HEK293/MRP1 cells with an average IC50 of 9.35 µM. Felbamate had the least growth 
inhibitory effect on HEK293/MRP1 cells with an average IC50 of 47.23 µM. Thus from 
table 2.3, we can infer that most HEK293/MRP1 cells survived when treated with 
felbamate hence requiring very high concentration of the drug to inhibit 50% of the cell 
growth. As expected HEK293/pcDNA 3.1 was very sensitive to the cytotoxic activity of 
all the test compounds as compared to HEK293/MRP1 cells since they do not overexpress 
MRP1, thus these cells can easily be impacted by the cytotoxicity of the drugs. Overall, the 
three ATP competitive inhibitors that decreased MRP1 protein expression were also very 




Table 2.3 Cytotoxicity of selected hit compounds on HEK293/pcDNA3.1 and 
HEK293/MRP1 cells  
Cell Line Drug IC50 
a
 (µM) 
   
 
SB743921 HCl 6.84 ± 0.73 
HEK293/pcDNA3.1 Amuvatinib 0.45 ± 0.25 
 
TG101348 (SAR302503) 2.05 ± 0.34 
 
Felbamate 14.92 ± 2.06 
 
SB743921 HCl 9.35 ± 0.12 
HEK293/MRP1 Amuvatinib 2.61 ± 0.64 
 
TG101348 (SAR302503) 3.26 ± 0.21 
 
Felbamate 47.23 ±0.64  
a 
Mean ± SEM of n ≥ 2 independent experiments  
 
3.5 Effect of selected test compounds on MRP1-mediated drug resistance 
One of the major setbacks of the current modulators of MRP1 is the fact that they exhibit 
low MDR reversal effects. Thus, we investigated the ability of the selected compounds to 
reverse MRP1 mediated resistance towards vincristine. HEK293 MRP1-overexpressing 
cells were treated with varying concentrations of vincristine in the presence or absence of 
non-cytotoxic concentrations of the test compounds. MK571 was used as positive control. 
As shown by the IC50 and fold resistance listed in table 2.4. HEK293 MRP1-overexpressing 
cells in the absence of MK571 demonstrated very low sensitivity to the cytotoxicity effect 
of vincristine, giving a high fold resistance of 20.51 fold. HEK293/pcDNA3.1 
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contrastingly exhibited very high sensitivity towards vincristine, thus gave a very low fold 
resistance. In the presence of MK571 inhibitor (25 µM), the fold resistance in the MRP1-
overexpressing cells drastically decreased from 20.51  to 3.64-fold resistance. From the 
results obtained, two of the selected compounds; Amuvatinib and TG101348 
(SAR302503) at 1 µM reversed MRP1-mediated resistance towards vincristine in 
HEK293/MRP1 cells. TG101348 (SAR302503) strongly decreased the fold resistance to 
7.16-fold, whilst Amuvatinib also reduced the fold resistance to 9.13-fold. This indicated 
that our selected test compounds may be able to reverse MRP1 mediated resistance. 
Contrastingly, treatment of HEK293/MRP1 with SB743921 HCl elevated the resistance of 
the cells against vincristine.  









HEK293/pcDNA3.1 3.11 ± 0.23 1 
HEK293/MRP1  62.25 ± 7.21 20.51 
HEK293/MRP1 + MK571 [25 µM] 11.30 ± 1.00 3.64 
HEK293/MRP1  + Amuvatinib [1µM] 28.42 ± 2.85 9.13 
HEK293/MRP1  + TG101348 [1 µM] 22.26 ± 4.78 7.16 
HEK293/MRP1  + SB743921 HCl [0.5 µM] 151.57 ± 20.75 48.78 
a  
Mean ± SEM  of at least three independent experiments performed in triplicates.  
b
 Fold resistance determined by dividing the IC50 value for each treatment by the IC50 




Recent advancement in chemotherapy has contributed to the improvement of survival rates 
of several cancers. However, MDR has been a prime opponent to this treatment modality. 
The occurrence of MDR in several carcinomas has limited the effectiveness of 
chemotherapy. The efflux activity of overexpressed MRP1 in tumor cells has been a key 
contributor to this phenomenon. The substrate family of MRP1 spans multiple drug classes, 
this includes conventional chemotherapeutic drugs such as etoposide, doxorubicin, 
paclitaxel among others [28]. It also affects the efficacy of antivirals, antibiotics, 
antimalarials among others [23]. As such, the overexpression of MRP1 by tumor cells is 
used as a survival and protection strategy to reduce the intracellular drug concentration and 
accumulation of such drugs to render them less potent by reducing their bioavailability. 
This goes a long way to reduce the cytotoxic effect of such drugs on cancer cells. This 
phenomenon in cancer cells has led to the elevated risk of treatment failure, and decreased 
survival rates of patients, thus pose a huge challenge to the pharmaceutical industry and 
clinical oncology researchers.  
Modulating the expression and function of MRP1 via biochemical modulation has become 
one of the powerful tools used by cancer researchers to overcome MPR1-mediated MDR. 
Biochemical modulation provides the platform for scientists to modulate the function and 
the transport in tumor cells without perturbing physiological homeostasis in normal cells. 
By using the biochemical modulation toolbox, two or more pharmacological agents that 
may work via varying molecular mechanisms and may have different molecular targets can 
be combined at their respective effective doses to achieve a common goal without eliciting 
any unacceptable side effects. Based on this principle, an inhibitor of MRP1 can be 
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combined with another chemotherapeutic agent with superior potency against tumor cells 
in one formulation. In this instance, the inhibitor can impede the efflux activity of MRP1 
to ensure that the other anticancer drug is bioavailable to yield the desired response and 
effect. Although some modulators of MRP1 have been identified in recent times, 
challenges like non-specific toxicity, low multidrug reversal effects, and undesirable off-
target effects limit their effectiveness. Thus, there is the need to identify more potent, well-
tolerated modulators with significant MDR reversal effects and limited non-specific 
toxicity.  
In this present study, we successfully screened 30 drugs which consisted of both anticancer 
and FDA drugs using an In-cell ELISA assay to identify modulators of MRP1 in HEK293 
MRP1-overexpressing cells. We identified 7 hit compounds (drugs that modulated MRP1 
protein expression above 50%) representing 23.33% of the total compound screened. Three 
of the hit compounds; Epirubicin HCl, Felbamate, and Irinotecan increased the protein 
expression of MRP1. Four of the hit compounds; Vismodegib (GDC-0449), TG101348 
(SAR302503), Amuvatinib, and SB743921 HCl decreased MRP1 protein expression in 
HEK293/MRP1 cells. Epirubicin HCl is an anthracycline that targets topoisomerase II [31]. 
Epirubicin HCl prevents DNA segregation and DNA synthesis by stabilizing the DNA – 
topoisomerase complex [32-36]. This antineoplastic agent is used in the treatment of breast 
cancer, and a known substrate of MRP1 [29]. Irinotecan is a derivative of Camptothecin 
that elicits its antitumor activity by inhibiting topoisomerase I (a nuclear enzyme that 
regulates the unwinding of DNA during replication) [37]. It is used in the treatment of 
metastatic colorectal cancer [38-41] and has been reported to be a substrate of MRP1 [28]. 
Vismodegib is a recently approved FDA drug that inhibits the hedgehog signaling pathway 
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[42]. This orally bioavailable small molecule is used in the treatment of locally advanced 
and metastatic unresectable basal cell carcinoma (BCC) [42]. Vismodegib is among the 
few small molecules that have been reported to inhibit the activity of MRP1 [30]. Since the 
impact of Epirubicin HCl, Irinotecan, and Vismodegib on MRP1 have already been 
reported in other studies, we focused on characterizing other hit compounds whose 
modulatory effects on MRP1 had not been reported.  
The novel drugs identified in our initial screening included; SB743921 HCl, Amuvatinib, 
TG101348 (SAR302503), and Felbamate. Except for Felbamate; SB743921 HCl, 
Amuvatinib, and TG101348 (SAR302503) based on their mode of action have been 
reported to be ATP competitive inhibitors. ATP competitive inhibitors are inhibitors that 
act by competing with ATP to block the activity of their targets [43]. These inhibitors are 
also known as Type 1 inhibitors. SB743921 HCl is a novel kinesin spindle inhibitor that 
elicits its function by impeding functional mitotic spindle formation in cell mitosis by 
hydrolyzing ATP [44], thereby regulating cell division. SB743921 HCl has been reported 
to show a strong inhibitory effect on ERK and AKT activity in chronic myeloid leukemia 
(CML) cells [45]. Although SB743921 HCl has been reported to have a strong inhibitory 
effect on tumor cells, its interaction with MRP1 as well as its effect on MRP1 activity and 
expression is yet to be reported. Amuvatinib on the other hand is an orally bioavailable 
small molecule that is reported to inhibit the activity of the MET receptor tyrosine kinase, 
c-KIT, and platelet-derived growth factor receptor (PDGFR) by competing with ATP for 
binding at the catalytic site [46]. This multi-targeted tyrosine inhibitor is currently in phase 
II clinical trials for the treatment of solid tumors [47, 48]. A recent study in our lab group 
that aimed at identifying novel inhibitors of MRP1 using a doxorubicin-based screening 
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assay revealed that Amuvatinib may inhibit MRP1 activity, however, its impact on MRP1 
protein expression as well as its ability to reverse MRP1 mediated resistance has never 
been reported. TG101348 (SAR302503) is an orally bioavailable selective inhibitor of 
Janus-associated kinase 2 [49-51]. It elicits its inhibitory effect by competing with JAK2 
for ATP binding , this results in JAK2 inactivation and subsequent inactivation of the JAK-
STAT pathway. Thereby inducing apoptosis in tumor cells. This ATP competitive inhibitor 
of  JAK2 was recently approved for the treatment of adult patients with intermediate-2 or 
high-risk primary or secondary myelofibrosis in the United States, and it is currently in 
phase III clinical trial for myelofibrosis treatment globally [49]. TG101348 (SAR302503) 
has also been reported to enhance the cytotoxic effect of imatinib (a well-known  drug for 
the treatment) of Chronic myeloid leukemia (CML) in residual CML cells [52]. It is also 
reported to impede growth of Hodgkin lymphoma and mediastinal large-cell lymphoma in 
both in vitro and in vivo studies [53]. Despite the success of TG101348 (SAR302503) in 
treatment of tumor cells, its interaction with MRP1 is yet to be reported. 
 In this study, we demonstrated using In-Cell ELISA assay that the ATP competitive 
inhibitors; SB743921 HCl, Amuvatinib, TG101348 (SAR302503) significantly 
downregulated the protein expression of MRP1 in HEK293 MRP1-overexpressing cells. 
For the first time, we report that SB743921 HCl and Amuvatinib demonstrate a 
concentration and time-dependent activity in modulating MRP1 protein expression with 
greater significance observed at concentrations above 10 µM and incubation periods above 
24 hours. We also showed that TG101348 (SAR302503) exhibited significant 
downregulation of  MRP1 protein expression at 10 µM and after 48 hours incubation 
period. Felbamate, an antiepileptic FDA approved drug, was also reported for the first time 
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to significantly increased the expression levels of MRP1 in HEK293 MRP1- 
overexpressing cells in this study. Significant upregulation of MRP1 protein expression 
was observed at concentrations above 10 µM and after 48 hours of incubation when cells 
were treated with felbamate. Although these drugs modulated MRP1 protein expression, 
further research must be conducted to evaluate if  SB743921 HCl, TG101348 
(SAR302503) are inhibitors of MRP1 and whether Felbamate is a substrate of MRP1. 
Moreover, further studies to determine the mechanism of interaction between these novel 
modulators and MRP1 would be a step in the right direction.  Nonetheless, it is possible to 
speculate that SB743921 HCl may downregulate MRP1 protein expression by obstructing 
the PI3/Akt signaling pathway. This is because the PI3/Akt signaling pathway has been 
reported to modulate MRP1 expression in human acute myeloid leukemia [54], and 
SB743921 HCl has also been reported to strongly inhibit this pathway [45]. However, 
further studies are needed to verify the involvement of the PI3/Akt pathway in the 
modulatory effect of SB746921 HCl on MRP1.  
We also evaluated the effect of these novel modulators on MRP1 efflux activity using the 
flow cytometry-based calcein accumulation assay. Our results demonstrate that SB743921 
HCl, TG101348 (SAR302503) can strongly inhibit MRP1 mediated calcein efflux. 
Amuvatinib which was previously reported to inhibit MRP1 mediated doxorubicin efflux 
in small cell lung cancer cells (H69AR) [55], also inhibited MRP1 mediated calcein efflux 
in HEK293 MRP1-overexpressing cells in this study. These results indicate that 
Amuvatinib may be able to inhibit efflux of several substrates of MRP1, making it an 
interesting therapeutic agent to explore in further studies. Contrastingly, we did not observe 
any significant inhibition in MRP1-mediated calcein efflux when cells were treated with 
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felbamate and compared to the no treatment control. This may be to the fact that the 
presence of felbamate upregulates MRP1 protein expression in these cells, as such increase 
the overall efflux of calcein as observed.  
We also showed that the three novel modulators that decreased MRP1 protein expression 
in this study are also able to inhibit the growth of HEK293 MRP1-overexpressing cells at 
clinically achievable concentrations (Table 2.3). This observation may be in synchrony 
with their ability to decrease MRP1 protein expression in these cells. Felbamate (average 
IC50 – 47.23 µM) on the other hand, was the least potent in inhibiting the growth of 
HEK293/MRP1 among the novel modulators identified. This may be because felbamate 
increases MRP1 protein expression as observed earlier in this study, thus it is easily 
effluxed by the transporter as such enhancing the survival of these cells and requiring a 
higher dose of drug treatment to achieve the half-maximal inhibitory effect. However, 
further research is needed to elucidate and verify the mode of interaction and action 
between felbamate and MRP1.  
One of the major limitations of current modulators of MRP1 is the inability of these 
modulators to reverse MRP1-mediated resistance. Thus, we investigated the ability of our 
identified novel modulators (SB743921 HCl, Amuvatinib, TG101348 (SAR302503)) to 
reverse MRP1- mediated resistance against vincristine in HEK293 MRP1-overexpressing 
cells. Amuvatinib and TG101348 (SAR302503) were most effective in reversing MRP1- 
mediated resistance in HEK293 MRP1 overexpressing cells (Table 2.4). TG101348 
(SAR302503) sensitized HEK293/MRP1 cells to the cytotoxic effects of vincristine, 
thereby reducing the average IC50 from 62.25µM to 22.26 µM with a fold reduction from 
20.51 to 7.16-fold resistance. Amuvatinib also reversed MRP1 mediated resistance towards 
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vincristine by decreasing the average IC50 from 62.25µM to 228.42 µM with a fold 
reduction from 20.51 to 9.13-fold resistance. Contrastingly, we observed that SB743921 
HCl enhanced resistance of HEK293 MRP1-overexpressing cells towards vincristine. Our 
results demonstrate that Amuvatinib and TG101348 (SAR302503) can reverse MRP1 
mediated MDR in MRP1 overexpressing cells. It would be of interest to investigate the 
ability of Amuvatinib, TG101348 (SAR302503) to reverse MDR mediated by MRP1 and 
other ABC transporters in other cell lines.  
Findings from this project indicate that the test compounds; SB743921 HCl, Amuvatinib, 
and  TG101348 (SAR302503) decreased MRP1 protein expression and its efflux activity,  
with Amuvatinib and  TG101348 (SAR302503) exhibiting high potency in reversing 
MRP1-mediated MDR. Therefore these aforementioned drugs can be used in the 
development of combinatorial drug therapy with an anticancer drug that is potent in 
targeting and treating cancer cells but is a substrate of MRP1. As such in cancer cells 
overexpressing the MRP1 transporter, administration of such formulations allow the 
modulator to downregulate the MRP1 expression levels enabling the anticancer drug to 
accumulate at the appropriate concentration and be bioavailable to elicit its desired effect. 
These interventions would go a long way to aid in our fight against tumor chemoresistance 
mediated by MRP1.  Our novel modulator, Felbamate which increased MRP1 protein 
expression in this study can also be used in the treatment of diseases whose etiology 
involves the down-regulation of MRP1 expression levels. For instance, Alzheimer’s 
disease is a neurodegenerative disorder that is pathologically characterized by the 
accumulation of beta-amyloid peptide (Aß) in the brain of its patients [56]. Studies by 
Krohn and his colleagues revealed that deficiency of MRP1/ABCC1 in mice models that 
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expressed Swedish human Aß precursor protein (APPswe) and mutant presenilin-1 (PSI) 
(APP/PSI mice x Abcc1-/-) resulted in elevated levels of cerebral beta-amyloid peptide 
(Aß) but did not affect the expression levels of enzymes responsible for the production of 
Aß from APP [57]. However, treatment with an MRP1 inducer, thiethylperazine resulted 
in decreased Aß levels in APP/PS1 mice brains. These results demonstrated the role of 
MRP1 in the clearance of Aß and its sequential accumulation in the brain. Thus in disease 
states like Alzheimer’s disease, drugs with a high potency of inducing and increasing 
MRP1 expression levels are desirable. Therefore,  our novel modulator, Felbamate which 
increased MRP1 protein expression in HEK293 MRP1 overexpressing cells in this study 
and is currently used for the treatment of Epilepsy can be a good candidate for treating such 
disorders. It would be a step in the right direction to investigate how Felbamate can be used 
in targeting and treating disorders in which MRP1 expression levels are down-regulated.   
In summary, we investigated the modulatory effect of a unique set of drugs on MRP1 
protein expression. We identified four novel modulators of MRP1 protein expression in 
HEK293 MRP1-overexpressing cells. We report for the first time that novel ATP 
competitive inhibitors; SB743921 HCl, Amuvatinib, TG101348 (SAR302503) 
downregulate MRP1 protein expression and activity. Findings from our work suggest that 
the identified modulators may limit toxicity and increase the effectiveness of overcoming 
MRP1 mediated MDR. Thus the drugs can be explored in combinatorial drug therapy 
aimed at targeting tumors with the MDR phenotype conferred by MRP1 overexpression. 
Drugs that showed little to low modulatory effect on MRP1 in our initial screening may 
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Tie2 kinase and mTOR targeted agents modulate MRP1 activity in MRP1-
overexpressing  cells 
Abstract 
Chemotherapy is the only systemic treatment for many cancers. Overexpression of MRP1 
in cancer cells facilitates the efflux of administered chemotherapeutic drugs, thereby 
reducing their intracellular drug concentration and bioavailability. This results in tumor 
cells becoming unresponsive and resistant to therapeutic agents. The development of 
multidrug resistance in cancer cells leads to increased risk of treatment failure and reduced 
survival chances of cancer patients. Finding ways of regulating the activities of MRP1 in 
overexpressed cells is of great pharmacological importance. We report that Tie2 kinase 
inhibitor and mTOR inhibitor, Everolimus modulate MRP1 activity in MRP1-
overexpressing cells. Tie2 kinase inhibitor and Everolimus decreased MRP1 mediated 
calcein efflux in HEK293 MRP1-overexpressing cells. However, these compounds did not 
affect the protein expression of MRP1 in HEK293 MRP1-overexpressing cells. In 
resistance reversal studies, Tie2 kinase inhibitor and Everolimus reversed MRP1-mediated 
resistance towards vincristine in these cells. Overall, data from this study indicates Tie2 
kinase inhibitor and Everolimus holds great potential for the development of therapeutics 
targeting MRP1-mediated multidrug resistance.  
 
 Keywords: ABC transporters; multidrug resistance; MRP1; ABCC1; MRP1 modulators; 
anticancer drug; drug profiling;  drug-transporter interactions, Tie2, mTOR 
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1) Tie2 Kinase Inhibitor  (PubChem CID: 23625762); 2) Everolimus (PubChem CID: 
6442177) 
1.0 Introduction 
Cancer is a global public health challenge with high morbidity and mortality. The potential 
of tumor cells to develop resistance to mechanistically and structurally discrete 
chemotherapeutic agents has become one of the major hindrances to the chemotherapy 
regime. This phenomenon is described in clinical cancer research as Multidrug resistance 
(MDR). The ATP binding cassette (ABC) transporters have been reported to be key players 
in the MDR development of several carcinomas. This superfamily of transporters is 
responsible for the efflux of a wide range of substrates in eukaryotes. These substrates 
include xenobiotics, toxins, drugs, and their metabolites [1]. Due to the essential role 
played by ABC transporters, cancer cells take advantage of their pivotal function to ensure 
their survival against administered anticancer drugs. This they achieve by overexpressing 
ABC transporters like P-glycoprotein (P-gp), Multidrug resistance protein 1 (MRP1), and 
Breast cancer resistance protein (BCRP). As such administered chemotherapeutic drugs 
are challenged by the efflux activity of these transporters as they serve as the first line of 
defense in tumor cells. The removal of drugs and their metabolites by the overexpressed 
ABC transporters across the plasma membrane has been associated with decreased 
bioavailability and reduced therapeutic efficacy of anticancer drugs on tumor cells.  
ABC transporters are a type of ATP-binding cassette pumps encoded by the ABC genes 
[2]. This superfamily of transporters is grouped into seven subfamilies, subfamilies A-G in 
humans. Most ABC transporters are characterized by a core unit consisting of membrane-
spanning domains (MSDs) which consist of six hydrophobic α-helices, and nucleotide-
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binding domains (NBDs). The NBDs form the powerhouse of the transporter, as it is 
responsible for ATP binding and hydrolysis for the generation of energy. The MSDs use 
the energy generated to facilitate substrate recognition and substrate translocation across 
the plasma membrane [3]. In recent times, the overexpression of the MRP1 transporter has 
been associated with the development of MDR in several carcinomas including ovarian 
cancer [4], childhood neuroblastoma, acute lymphoblastic leukemia[5]. MRP1 is a member 
of the ABCC subfamily of ABC transporters. It is encoded by the gene ABCC1 [6]. MRP1 
localizes at the basolateral membrane and is expressed in the epithelial cells of organs like 
the adrenal gland, testes, kidney, gastrointestinal tract, and at pharmacological sacred sites 
like the blood-brain barrier, blood-cerebrospinal fluid barrier, and the blood-testes barrier 
[7, 8]. Substrates of MRP1 include; heavy metals, leukotrienes, prostaglandins, glutathione 
(GSH), and glucuronide-conjugates of steroids [9, 10]. MRP1 also transports drugs from 
various drug classes including; anthracyclines (doxorubicin), folate-based antimetabolites 
(methotrexate), antivirals (saquinavir), antibiotics (difloxacin), plant alkaloids (etoposide, 
paclitaxel) among others [11]. Due to the critical role MRP1 plays, and its ability to interact 
with a wide range of drug families; its overexpression has been a destructive tool used by 
cancer cells to efflux administered drugs out of the intracellular space in cancer patients 
rendering these drugs less bioavailable to exert the desired effect. This phenomenon has 
created a huge barrier to the effectiveness of chemotherapy and reduced survival rates of 
cancer patients [12]. 
Finding ways of regulating the activities of MRP1 in overexpressed cells is of great 
pharmacological essence. One approach is to curb this canker is to completely shut down 
the efflux transporter, MRP1. Although this strategy may seem laudable; it would be 
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suicidal for the cells as MRP1 is a key regulator of physiological homeostasis in cells. 
MRP1 aids to maintain the GSH/GSSG (Oxide GSH) ratio to ensure redox homeostasis in 
cells [13]. Moreover, the transport activity of MRP1 helps to prevent the accumulation of 
toxicants and the buildup of estrogen-like compounds in the testes which aid to prevent 
testicular feminization and protect developing spermatozoa  [8, 14]. MRP1 also functions 
to protect the heart by facilitating the efflux of toxic products of oxidative stress from the 
mitochondria and cardiomyocytes [15]. From the aforementioned roles played by MRP1 
in maintaining physiological balance in cells, the complete shutdown of the transporter 
would cause significant perturbations in the physiological balance of cells. An alternative 
approach that can be utilized to regulate the activity of the transport in tumor cells without 
disturbing the physiological equilibrium, is to use the biochemical modulation toolbox. 
Biochemical modulation involves the use of therapeutic agents including small molecules 
to achieve selective manipulation of tumor cell metabolism or signal transduction pathways 
to ensure the more selective response of tumor cells to the action of anticancer drugs [16].  
The phosphoinositide 3 kinases/Akt (PI3K/Akt) signal transduction pathway has been 
reported as one of the cellular pathways that regulate the expression levels of MRP1 [17, 
18]. PI3K is a lipid kinase involved in the regulation of biological events such as migration, 
metabolism, survival, and also activates a lot of downstream proteins [19]. Serine 
(Ser)/Threonine (Thr) kinase also known as Akt or protein kinase B regulate the expression 
and activity of numerous proteins including MRP1 [20, 21]. This pathway has been 
reported to be involved in MDR observed in breast cancer, lung cancer. ovarian cancer, 
melanoma, and hepatocellular carcinoma [18-23]. As such, this pathway offers a great 
avenue for the development of novel strategies to target MRP1 in MDR.  Moreover, 
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exploring the impact of activators and downstream effectors of this pathway on MRP1 
activity and expression would aid in identifying potential therapeutic targets for the 
development of more efficacious and specific therapeutics for targeting MRP1 mediated 
MDR and treating cancer patients [18]. Tunica interna endothelial cell (Tie2) tyrosine 
kinase receptor is an endothelial cell-specific receptor which activates the PI3/Akt pathway 
in normal endothelial cells [22]. It has been associated with the extravascular compartment 
of several tumors such as inflammatory breast cancer, leukemia, gastric, and thyroid tumors 
[23]. mTOR (mammalian target of rapamycin) on the other hand is a serine/threonine 
kinase that modulates the diverse nutritional and environmental cues like amino acids, 
growth factors, cellular stress among others in cells [24]. Moreover, mTOR is also reported 
to function downstream the PI3K/Akt signaling pathway and has been involved in the 
etiology of several cancers [24, 25]. In this study, we investigated the effect of a novel 
inhibitor of Tie2 (Tie2 kinase inhibitor) and mTOR inhibitor (Everolimus) on MRP1 
activity and protein expression in MRP1-overexpressing cells using established methods. 
We also determined the ability of these drugs to reverse MRP1-mediated resistance in 




2.0 Materials and methods 
2.1 Chemicals  
Test compounds were procured from APExBIO Technology LLC (Houston, TX). MK571 
was acquired from APExBIO Technology LLC (Houston, TX), thiazolyl blue tetrazolium 
bromide (MTT) were procured from Sigma-Aldrich (St. Louis, MO).and Calcein 
acetoxymethyl ester (Calcein-AM) was obtained from Corning Life Sciences (Corning, 
NY). 
 
2.2 Cell lines and cell culture 
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modified Eagle medium 
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine 
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a 
humidified incubator maintained at 5% CO2 and 37 °C. This incubation condition was 
retained in all subsequent cell culture procedures. 
 
2.3 Flow cytometry-based calcein accumulation assay 
The effect of Tie2 kinase inhibitor and Everolimus on MRP1 mediated efflux of calcein-
AM was ascertained using flow cytometry. HEK293 MRP1-overexpressing cells were 
prepared in serum-free medium at a cell density of  7 × 105 cells/ml and treated with 10 
µM of test compounds for 10 minutes at 37 °C. Cells were then treated with calcein-AM 
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(0.25 µM) for 30 minutes. Final DMSO concentration was maintained at 0.1% (v/v). MRP1 
mediated efflux activity was stopped using ice-cold PBS buffer (3 ml). Cells were 
collected, washed twice with PBS, and resuspended in a cold PBS buffer containing 1% 
paraformaldehyde. Intracellular calcein-AM fluorescence was detected using BD Accuri 
C6 flow cytometer ( BD Biosciences, San Jose, CA) with excitation and emission at 480 
nm and 533/30 nm respectively. Fluorescent intensity was determined as a mean of 10000 
events. Treatments were done in duplicates and experiments were performed in three 
independent studies. 
 
2.4  Determination of concentration-dependent activity on MRP1 protein expression 
using western blot assay.  
 HEK293/MRP1 and HEK239/pcDNA 3.1 (parental control) cells were seeded at 7x105 
cells per well in 6-well plates with DMEM containing 10% FBS and incubated for 24 
hours. Cells were treated with varying concentrations of drugs; 5 µM, 10 uM, 20 µM,  and 
0.1% DMSO for controls, and incubated for  48 hours at 37 °C. At the end of the incubation 
period, the spent media was removed and cells were rinsed with 1000 μl of PBS. The cells 
were lysed with lysis buffer containing radioimmunoprecipitation assay buffer (RIPA 
Buffer, Thermo Fisher Scientific, Waltham, MA) supplemented with 1× halt protease 
inhibitor cocktail (to inhibit the activity of cell proteases). Protein concentration was 
determined with the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, 
Waltham, MA) using bovine serum albumin as standard. Proteins (20 μg) were loaded in 
each well and sodium dodecyl sulfate (SDS) page electrophoresis was conducted on 8.0% 
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mini SDS gels, after which proteins were transferred to  Immobilon PVDF membranes 
(EMD Millipore, Burlington, MA) for 4 hours. The membrane was blocked with 5% 
bovine serum albumin (BSA) in Tris Buffered Saline -Tween 20 (TBS-T,0.1%),  and 
washed with TBS-T (0.1%; 3× per 10mins). Followed by incubation (4 °C, overnight) with 
monoclonal MRP1 antibody [EPR21062](ab233383) and anti-GAPDH antibody (Thermo 
Fisher Scientific, AM4300) dissolved in TBS-T (0.1%) with BSA (1%)  at 1:250 and 
1:1000 dilutions respectively. The membrane was washed with TBS-T (0.1%, 3× per 
10mins) and incubated with secondary antibody using horseradish peroxidase-conjugated 
goat anti-mouse IgG(H+L) (Thermo Fisher Scientific) for alpha-tubulin detection, and 
horseradish peroxidase-conjugated goat-anti-rabbit IgG(H+L) (Thermo Fisher, Scientific) 
for MRP1 detection. Target proteins were detected using Western blotting luminol reagent 
(Santa Cruz Biotechnology, sc-2048). Signals were quantified using Image Studio Lite 
version 5.2 and normalized by using the intensity of the corresponding protein band relative 
to the GAPDH band. 
 
2.5 In vitro cytotoxicity assay 
The cytotoxicity effect of the test compounds was investigated by using the MTT 
colorimetric assay. HEK293/MRP1 and HEK293/pcDNA3.1 cells were seeded in 96 well 
plates at a cell density of 5 ×103 per 100 ul of culture medium and incubated overnight. 
Cells were treated with varying concentrations of the test compound diluted in medium and 
were incubated for 72 hours. At the end of the incubation period, 100 ul of spent media 
was carefully decanted. MTT (0.5 mg/ml) treatment was conducted for 4 hours. Dissolution 
of formazan crystals was done by the addition of 100 ul of 15% SDS containing 10 mM 
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HCl, absorbance was read at 570 nm using a Hidex Sense Beta Plus plate reader (Turku, 
Finland). Treatments were performed in triplicates and repeated in two independent 
experiments.  
 
2.6 MDR reversal activity of test compounds 
Reversal of resistance effect of  Tie2 kinase inhibitor and Everolimus was determined using 
MTT assay. Cells were seeded at a cell density of 5×103 per 100 ul of culture medium in 
96 well plates and incubated for 24 hours at 37°C to allow cells to attach. Drug treatment 
was then conducted by treating cells with 150 ul of test compounds at selected non-
cytotoxic concentrations. The addition of varying concentrations of vincristine (50 µl) was 
conducted after an hour. MTT treatment (0.5 mg/ml) was conducted for 4 hours. The 
formazan crystals were dissolved by the addition of 100 ul of 15% SDS containing 10 mM 
HCl and absorbance at 570 nm was recorded using a Hidex Sense Beta Plus plate reader 
(Turku, Finland). Treatments were done in triplicates, and experiments were performed in 
two independent studies. 
 
2.7 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism TM software (GraphPad 
Software version 8.4.3, San Diego, CA, USA). The differences between mean values were 
analyzed using linear mixed model analysis. Sidak correction was applied for multiple 




3.1 Effect of test compounds on MRP1 efflux activity 
Calcein-AM is a common substrate of MRP1 and is widely used to study MRP1 mediated 
efflux. When the acetoxymethyl ester (AM) moiety of calcein is cleaved by esterases in 
cells, calcein becomes fluorescent. The impact of MRP1 efflux activity was investigated 
using flow cytometry. The structures of Tie2 kinase inhibitor and Everolimus are shown in 
Figure 3.1. As shown in Figure 3.2, HEK293 MRP1-overexpressing cells in the absence of 
MK571 showed very low retention of calcein whilst in the presence of MK571 (25µM), 
the accumulation of calcein strongly increased by 3.85 fold . HEK293/MRP1 cells in the 
presence of Tie2 kinase inhibitor and Everolimus also increased the accumulation of 
calcein in the cells approximately by 3.96-fold and 3.83-fold respectively. The fold 
increase in calcein accumulation in the presence of the test compounds was very 
comparable to the positive inhibitor, MK571. This finding suggests that Tie2 kinase 
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Figure 3.2 Effect of test compounds on MRP1 efflux activity.  
HEK293/MRP1 cells were treated with 10 µM of the test compounds and 25 µM of MK571 
(positive control) for 10 minutes at 37 °C before treatment with 0.25 µM calcein-AM for 
an hour, Flow cytometric measurements of intracellular calcein-AM was conducted at 488 
nm and 533/30 nm for excitation and emission wavelengths, respectively. Experiments 
were done as duplicates in three independent experiments and presented as mean ± S.E.M. 
Data was analyzed using a linear mixed model and Sidak post hoc test. *P < 0.05; **P < 




3.2 Effect of test compounds on MRP1 protein expression levels 
To determine the influence of Tie2 kinase inhibitor and Everolimus on MRP1 protein 
expression, we conducted a western blot assay using varying concentrations of the test 
compounds (5 µM, 10 µM, 20 µM) (Figure 3.3A). The protein expression levels of MRP1 
was not significantly impacted when HEK293 MRP1-overexpressing MRP1were treated 
with 5 µM, 10 µM, and 20 µM of test compounds and compared to the protein expression 







Figure 3.3 Effect of test compounds on MRP1 protein expression. 
 [A] Shown are representative western blots of whole-cell lysates (20ug of protein/lane) 
prepared from HEK293/pcDNA3.1 and HEK293/MRP1 cells treated with varying 
concentrations of test compounds (5 µM, 10 µM, 20 µM), and 0.2% DMSO (controls) for 
48 hours. MRP1 proteins were detected with monoclonal anti MRP1 antibody 
[EPR21062](ab233383, Abcam) and anti-GAPDH antibody (Sigma-Aldrich) at a dilution 
of 1:250 and 1:1000 respectively. Secondary antibodies; mAb - anti-rabbit and mAb-anti-
goat were used at a dilution of 1:1000. Whole cell lysates were run on 8% SDS gel for one 
hour before being transferred to the pretreated PVDF membrane. Three independent 
experiments were conducted, and data presented as mean ± S.E.M. [B] Protein band density 
was analyzed using the Image Studio Lite (LI-COR Biotechnology) software and corrected 
for uneven sample loading and transfer using GAPDH as the loading control. Data was 





3.3 Impact of test compounds on MRP1-mediated resistance 
Although recent advancement in chemotherapy has resulted in improved survival rates of 
cancer patients, multidrug resistance (MDR) in tumor cells possess a great limitation on its 
success. Thus, we investigated the ability of Tie2 kinase inhibitor and Everolimus to 
reverse MRP1 mediated resistance towards vincristine. Vincristine is a commonly used 
anticancer drug, that is used in the treatment of several carcinomas. Unfortunately, MRP1 
is reported to mediate the resistance of tumor cells to vincristine. As presented in Figure 
3.4, HEK293 MRP1-overexpressing in the absence of MRP1 (solid red) demonstrated very 
high resistance to vincristine cytotoxic effect giving a fold resistance of 19.96 folds (Table 
3.1). The parental cell line HEK293/pcDNA3.1(dotted blue) which does not overexpress 
MRP1 showed low resistance to vincristine (Figure 3.4). In the presence of MK571 (25 
µM), HEK293/MRP1 cells became more sensitive to the cytotoxic effect of MK571 
resulting in reducing the fold resistance observed in these cells to 3.75 fold resistance 
(Table 3.1). Our test compounds also reversed MRP1 mediated resistance towards 
vincristine in HEK293/MRP1 cells. Everolimus (dotted purple) and Tie2 kinase inhibitor 
(dotted orange) decreased vincristine resistance to 7.01-fold resistance  and 8.91-fold 












Figure 3.4 Effect of Tie2 kinase inhibitor and Everolimus on drug sensitivity of 
HEK293 MRP1-overexpressing cells towards vincristine.  
Cells were treated with increasing concentrations of vincristine in the absence or presence 
of a non-cytotoxic concentration of test compounds. MK571 (25 µM) served as the positive 
control. MTT assay was conducted to determine cell viability after 72 hours. Data is 
representative of three independent experiments and expressed as mean ± SEM. 





























Table 3.1 Effect of selected Tie2 Kinase Inhibitor and Everolimus on the IC50 values 
of vincristine in HEK293/MRP1 cells 
Cell line/Treatment IC50
a (nM) 
  Vincristine Fold resistanceb 
HEK293/pcDNA3.1 3.11 ± 0.23 1.00 
HEK293/MRP1  62.02 ± 4.33 19.96 
HEK293/MRP1 + MK571 [25 µM] 11.65 ± 1.79 3.75 
HEK293/MRP1  + Everolimus [5 µM] 21.78 ± 3.34 7.01 
HEK293/MRP1  + Tie2 Kinase Inhibitor [1] µM 27.67 ± 1.09 8.91 
a  Mean ± SEM  of at least three independent experiments performed in triplicates.  
b Fold resistance determined by dividing the IC50 value for each treatment by the IC50 






Chemotherapy is the standard treatment for systemic cancer in both metastatic and locally 
advanced carcinomas. Although chemotherapy has been beneficial for treating cancer, 
patients perpetually experience recurrence after therapy and exhibit a multidrug-resistant 
phenotype [26]. The development of the multidrug-resistant phenotype in tumor cells is 
resulted in tumor cells becoming unresponsive and insensitive to a variety of 
chemotherapeutic agents [27]. This phenomenon is termed Multidrug resistance (MDR). 
MDR has become one of the major challenges to the success of chemotherapy. The 
overexpression of  ABC transporters like MRP1 has been associated with the development 
of MDR in tumor cells. MRP1 like other ABC efflux transporters utilizes energy from ATP 
hydrolysis to facilitate the efflux of its substrate across biological membranes. 
Overexpression of MRP1 has been associated with increased drug efflux resulting in 
reduced intracellular effective drug concentration of a wide range of anticancer agents 
(doxorubicin, vincristine, methotrexate), thereby contributing to MDR and elevated 
chemotherapeutic failure [17, 28]. Recent studies have aimed at identifying novel strategies 
to modulate the structure and function of MRP1 in order to regulate its activity in the MDR 
of tumor cells. Some modulators like MK571, ONO-1078, probenecid, indomethacin have 
been identified in recent times [29], yet some dreadful side effects and elevated patient 
toxicities due to these modulators have limited the possibility of translating these promising 
therapeutics from the bench side to the clinic. Thus there is the need for more potent and 
safer MRP1 modulators.  
Regulating effectors of signaling pathways that have been reported to be associated with 
MDR can aid discover new and ideal strategies for developing targeted therapeutics for 
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MRP1-mediated MDR. In this study, we successfully explored the effect of novel Tie2 
kinase inhibitor and mTOR inhibitor, Everolimus, on MRP1 activity and expression in 
HEK293 MRP1-overexpressing cells. To the best of our knowledge there no evidence 
indicating the interaction between Tie2 kinase inhibitor and MRP1. Thus we report for the 
first time that Tie2 kinase inhibitor downregulates MRP1 mediated calcein efflux in 
HEK293 MRP1- overexpressing cells. Tie2 kinase inhibitor is an optimized compound of 
SB203580 which is highly selective for the Tie2 tyrosine kinase receptor [30]. Tie2 kinase 
inhibitor is reported to show inhibitory activity against Tie2 and also inhibit angiogenesis 
in MOPC-315 plasmacytoma xenograft model [30]. Tie2 tyrosine kinase receptor is also 
known as angiopoietin-1 receptor or Tek. The Ang-Tie2 system is reported to play roles in 
endothelial cell survival and proliferation, vascular plasticity, and angiogenesis [31]. It is 
also reported to activate the Akt in the P13/Akt signaling pathway which is known to 
modulate the activity of MRP1 expression and activity. Tie2 has been implicated in several 
tumors [23]. For instance, studies by Martin et al. showed that Tie2 signaling is associated 
with MDR in human glioma cells by upregulating ABC transporters [23]. Thus the 
downregulation of MRP1 efflux activity by Tie2 kinase inhibitor observed in this present 
study may be mediated via disruption of the Tie2 signaling pathway and subsequent 
deactivation of the PI3/Akt pathway signaling. However, it will be of great interest to 
ascertain the mechanism of action and interaction of the Tie2 kinase inhibitor and the 
MRP1 inhibitor. In addition to downregulating the MRP1 efflux activity, Tie2 kinase 
inhibitor also strongly reversed MRP1- mediated resistance in HEK293 MRP1-
overexpressing cells. Treatment of cells with Tie2 kinase inhibitor reversed resistance 
against vincristine by decrease the average IC50 from 62.02 µM (vincristine only treatment) 
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to 27.67 µM with the corresponding reduction in fold resistance from 19.96-fold resistance 
to 8.91-fold resistance. As such, Tie2 kinase inhibitor may be a potent candidate for 
modulating MRP1 mediated chemoresistance in tumor cells.  Treatment of HEK293 
MRP1-overexpressing cells with 5 µM, 10 µM, 20 µM of Tie2 kinase inhibitor did not 
yield any significant alteration on MRP1 expression in this cell line. Studies by Martin and 
his colleagues also reported that Tie2 upregulation did not have any significant impact on 
mRNA levels of MRP1/ABCC1 in human glioma cells [26]. Thus considering our results 
from this study and the observation reported from the previous study [26], modulation of 
Tie2 signaling may affect MRP1 activity but not modulate its expression levels. However, 
it would be enlightening to investigate the effect of Tie2 kinase inhibitor on MRP1 
expression levels in other cell lines. Findings from this study suggest that the Tie2 kinase 
receptor may be a potential molecular target for the development of efficacious and specific 
therapeutics for targeting and treating MRP1 mediated MDR. 
The use of Rapamycin and rapalogs (inhibitors of mTOR) have proven promising clinical 
efficacy in chemotherapy. In this study, we demonstrated that rapamycin analog, 
Everolimus down-regulates the MRP1 mediated calcein efflux in HEK293 MRP1-
overexpressing cells.  Everolimus elicits its function by binding to cyclophilin, FKBP-12 
which in turn binds to mTOR and forms the mTORC1 complex when it is associated with 
raptor and MLST8 and inhibits downstream signaling [32]. mTORC1 complex is 
implicated in the regulation and ordination of cell cycle progression, growth, and 
metabolism [33-37]. mTORC1 is a downstream effector of the PI3/Akt pathway which has 
been reported to modulate ABC transporters including MRP1. Thus Everolimus may elicit 
its effect on MRP1 by modulating this pathway. In this present study, we demonstrate that 
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Everolimus can also reverse MRP1 mediated calcein efflux in HEK293 MRP1-
overexpressing cells. Everolimus in this present study successfully decreased the fold 
resistance of HEK293 MRP1-overexpressing cells towards vincristine from 19.96-fold 
resistance to 8.91-fold resistance. Although Everolimus has been previously reported to 
downregulate MRP1 expression levels in cisplatin-resistant gastric cancer cell line [38], 
treatment of HEK293 MRP1-overexpressing cells with 5 µM, 10 µM, 20 µM of 
Everolimus did not significantly alter protein expression levels in this study. It is not 
uncommon to observe cell line-specific effects of a drug, moreover, the HEK293 MRP1-
overexpressing cells were generated by transfection as such these cells can possess very 
different membrane dynamics and molecular profiles. 
In summary, we successfully demonstrated the effect of novel Tie2 kinase inhibitor and 
mTOR inhibitor, Everolimus, on MRP1 activity and expression on HEK293 MRP1-
overexpressing cells. We showed that these drugs downregulate MRP1 activity and can 
reverse MRP1-mediated resistance. Thus these therapeutic agents are good candidates for 
developing combinatorial therapeutic strategies for the modulation of MRP1 mediated 
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Identification of FDA approved drugs as modulators of Multidrug Resistance Protein 
2 (MRP2/ABCC2) expression levels in MRP2-overexpressing cells 
Abstract 
Multidrug Resistance Protein 2 (MRP2) is an ATP-dependent transmembrane protein that 
plays a pivotal role in the efflux of a wide variety of physiological substrates across the 
plasma membrane. Several studies have shown that MRP2 can significantly affect the 
absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles of many 
therapeutic drugs as well as chemicals found in the environment and diet. This transporter 
can also efflux newly developed anticancer agents that target specific signaling pathways 
and are major clinical markers associated with multidrug resistance (MDR) of several types 
of cancers. MDR remains a major limitation to the advancement of the combinatorial 
chemotherapy regimen in cancer treatment. In addition to anticancer agents, MRP2 also 
reduces the efficacy of various drug classes such as antivirals, antimalarials, and 
antibiotics. The unique role of MRP2 and its contribution to MDR makes it essential to 
profile drug-transporter interactions for all new and promising drugs. Thus, this current 
research seeks to identify modulators of MRP2 expression levels using cell-based assays. 
A unique recently-approved FDA library (372 drugs) was screened using a high throughput 
In-Cell ELISA assay to determine the effect of these therapeutic agents on protein 
expression levels of MRP2. A total of 49 FDA drugs altered MRP2 expression levels by 
more than 50% representing 13.17% of the compounds screened. Among the identified 
hits, fifty-four (54) drugs increased expression levels whereas 12 drugs lowered expression 
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levels of MRP2 after drug treatment. Our findings from this initial screening showed that 
modulators of MRP2 peregrinates multiple drug families, and signifies the importance of 
profiling drug interactions with this transporter. Data from this project provides essential 
information to improve combinatorial drug therapy and precision medicine as well as 
reduce drug toxicity of various cancer chemotherapies. 
 
Keywords: ABC transporters; multidrug resistance; MRP2; ABCC2; MRP2 modulators; 






MRP2 (ABCC2) is a member of the ATP-binding cassette superfamily of transporters, 
MRP1 and MRP2 are homologous members of this superfamily [1]. In humans, it is 
encoded by the gene ABCC2 [2]. Structurally, MRP2 is a 190-kDa membrane protein 
consisting of 1545 amino acids. The predicted membrane topology consists of 17 
transmembrane spanning domains (MSD0, MSD1, MSD2) which are linked together by 
conserved linker regions, and two highly conserved nucleotide-binding domains (NBD1 
and NBD2) that serve as substrate – binding sites [3] as shown in Figure 4.1. 
 
 
Figure 4.1: The full-length model of the MRP2 protein 






Whilst MRP1 localizes at the basolateral membrane of endothelial cells, MRP2 localizes 
at the apical membrane of polarized cells of hepatocytes, renal proximal tubular cells, 
enterocytes, and syncytiotrophoblasts of the placenta [4]. It is known to play critical roles 
in the export of conjugated bile salts in the liver as well as transport of physiological 
important substrates such as glutathione-S-conjugates, 17-beta-glucuronsyl estradiol, 
leukotriene C4 [5]. Overexpression of MRP2 is associated with multidrug resistance of 
tumor cells such as hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas 
[6], where it pumps drug conjugates and drug complexes across the plasma membrane into 
the extracellular space [5]. Thus affecting the bioavailability and efficacy of anticancer 
drugs like cisplatin and methotrexate. Aside cancer drugs, MRP2 also affects the efficacy 
of a broad spectrum of drug classes including HIV drugs (lopinavir), antibiotics(ampicillin, 
azithromycin), and antihypertensives(Olmesartan, Temocaprilate) [7]. With MDR being a 
major impediment to the chemotherapy regime and the overexpression of the MRP2 
transporter being a major factor in this phenomenon, it is of great clinical interest to find 
ways of addressing this canker. Two main approaches have been proposed by researchers. 
One of which, is to completely block the efflux or pump activity of the transporter in these 
cells [8]. However, this approach would be destructive to the cells since it may also impede 
some important physiological activities of the transporter, thereby jeopardizing the overall 
wellbeing and physiological homeostasis of the cell or tissue. Another possible approach 
that was proposed, was to modulate the activity of this transporter using biochemical 
modulation. Using biochemical modulation, exogenously supplied metabolites can be used 
to selectively manipulate the activity of MRP2 in tumor cells to ensure the more selective 
response of cancer cells to the action of administered anticancer agents [9]. This would go 
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a long way to improve the bioavailability and efficacy of anticancer drugs in tumor cells. 
Hence the identification of possible modulators of the MRP2 transporter is of great clinical 
importance [8]. Moreover, the broad impact of the efflux activity of this transporter on the 
efficacy of a broad class of drugs makes it essential to investigate the possible interactions 
between various therapeutic drugs (both approved and those in clinical trials) and this 
transporter. Thus in this study, a unique set of drugs from the FDA approved drug library 




2.0 Materials and methods 
2.1 Chemicals  
FDA( Food and Drug Administration) approved drug library was procured from Selleck 
chemicals (Houston, TX). Super signal West Dura® Extended Duration 
chemiluminescence substrate (21EAPI34076) was obtained from Thermo Fisher Scientific 
(Waltham, MA). 
2.2 Cell lines and cell culture 
MDCKII, MDCKII/MRP2 cells were kindly provided by Dr. Alfred Schinkel (Netherlands 
Cancer Institute, Amsterdam, The Netherlands). MDCKII cell lines were grown in 
Dulbecco’s modified Eagle medium (DMEM) (GE Healthcare, Marlborough, MA, USA) 
enriched with 10% fetal bovine serum (FBS). Cell lines were cultured in a humidified 
incubator maintained at 5% CO2 and 37 
◦C. This incubation condition was retained in all 
subsequent cell culture procedures. 
 
2.3 Screening of FDA approved drug library using  In-Cell ELISA assay in 
MDCKII/MRP2 cells 
In-Cell ELISA assay development and optimization were performed with MDCKII and 
MDCKII/MPR2 cells and used to screen the FDA approved drug library for modulators of 
MRP2 protein expression. MDCKII/MRP2 cells were seeded at 7x104 cells per well in 96-
well plates with Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal 
bovine serum and incubated for 24 hours. Cells were then treated with drugs (10 uM),  and 
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0.1% DMSO (control and Parental) and incubated for 48 hours at 37°C. At the end of the 
incubation period, treatment was removed and cells were rinsed twice with 150 μl of  PBS. 
Cells were fixed with 3.7% paraformaldehyde and permeabilized with Triton-X 100. The 
cells were blocked using fish gel (MB-066-0100, Rockland) and incubated overnight at  4 
°C with monoclonal anti-MRP2 antibody (MABN1545, EMD Millipore) or anti-α tubulin 
antibody (T5168, Sigma-Aldrich) in a 1:1000 dilution. Secondary antibody incubation was 
performed using horseradish peroxidase-conjugated goat anti-mouse IgG (H + L) (Thermo 
Fisher Scientific, Waltham, MA) for an hour at room temperature. Target proteins were 
detected using Super signal West Dura® Extended Duration Substrate chemiluminescence 
substrate (21EAPI34076, Thermo Fisher Scientific) and read using Hidex Sense Beta Plus 
plate reader (Turku, Finland).  Treatments were performed in triplicates and expressed as 
means. Drugs that showed modulation of MRP2 protein levels above 50% were selected 





3.1 Screening of FDA approved drug library for modulators of MRP2  
The FDA approved drug library containing 372 drugs was successfully screened using In-
Cell ELISA assay using MRP2-overexpressing MDCKII cells. Treatments were performed 
in triplicates, and experiments were done using the 96 – well format. The relative MRP2-
modulation by the FDA approved drugs is presented in Figure 4.2. Data obtained was 
statistically analyzed and expressed as means. Drugs showing more than 50% modulation 
on MRP2 protein expression were selected as “Hit compounds”. The results revealed 49 
hit compounds that changed the MRP2 protein expression by more than 50%, representing 
13.17% of total compounds screened. Among the identified hits for MRP2, 39 drugs 
increased expression levels whereas 10 drugs lowered expression levels of MRP2 after 
drug treatment as shown in Figure 4.3. Details on the hit test compounds identified from 







Figure 4.2: In-Cell ELISA assay screening for modulators of  MRP2 protein 





Figure 4.3: Screening of 372 FDA  approved drug library using In-Cell ELISA assay  
Forty-nine (13.17%) hit compounds altered the MRP2 expression levels by more than 50%. 
Thirty-nine (10.48%) drugs increased expression levels whereas 10 (2.69%) drugs lowered 




Table 4.1 List of hit compounds identified from FDA screening on MRP2 protein 
expression  
Drug Target % Modulation on 
MRP1 protein levels a 
Pralatrexate (Folotyn)  DHFR -57.39 ± 3.85 
Cetirizine Dihydrochloride Histamine Receptor 106.29 ± 22.62 
Mercaptopurine DNA/RNA Synthesis 112.77 ± 15.36 
Streptozotocin (Zanosar) Nicotinamide  
adenine dinucleotide 
107.57 ± 13.87 
Dexamethasone IL Receptor 257.86 ± 10.58 
Megestrol Acetate Androgen Receptor 124.35 ± 26.22 
Trilostane Dehydrogenase 66.04 ± 4.96 
Ranolazine dihydrochloride Calcium Channel 93.67 ± 39.42 
Repaglinide Potassium Channel 94.45 ± 12.23 
Sildenafil Citrate PDE 70.30 ± 17.82 
Gestodene Estrogen/progestogen Receptor 54.07 ± 4.05 
Isotretinoin Hydroxylase 67.87 ± 5.05 
Nafamostat Mesylate Proteasome 84.25 ± 14.38 
Ondansetron 
hydrochloride (Zofran) 
5-HT Receptor 68.23 ± 7.83 
Oxcarbazepine Sodium Channel 75.54 ± 22.66 
a Mean ± SD  
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Table 4.2 List of hit compounds identified from FDA screening on MRP2 protein 
expression  
Drug Target % Modulation on 
MRP1 protein levels a 
Afatinib (BIBW2992) EGFR, HER2 -62.24 ± 20.67 
Gefitinib (Iressa) EGFR 85.68 ± 14.81 
Crizotinib (PF-02341066) c-Met 56.41 ± 9.37 
Sunitinib Malate VEGFR, PDGFR, c-Kit, Flt 71.59 ± 11.40 
Cladribine DNA/RNA Synthesis -74.96 ± 2.30 
Evista (Raloxifene Hydrochloride) Estrogen/progestogen Receptor 69.87 ± 7.06 
2-Methoxyestradiol HIF 148.42 ± 46.91 
Asenapine Adrenergic receptor,  
5-HT receptor 
-73.49 ± 5.67 
Adrucil (Fluorouracil) DNA/RNA Synthesis -62.54 ± 1.78 
Vincristine Microtubule Associated 216.85 ± 46.37 
Oxaliplatin (Eloxatin) DNA/RNA Synthesis 100.88 ± 10.98 





Table 4.3 List of hit compounds identified from FDA screening on MRP2 protein 
expression  
Drug Target % Modulation on MRP1 
 protein levels a 
Glyburide (Diabeta)  Potassium channel -77.59 ± 3.61 
Adefovir Dipivoxil (Preveon, 
Hepsera) 
reverse transcriptase -87.87 ± 5.68 
Sulfadiazine Anti-infection 69.784 ± 19.01 
Suprofen (Profenal) COX-1/COX-2 108.14 ± 22.69 
Cefditoren pivoxil 5-alpha Reductase 68.25 ± 9.12 
Rifabutin (Mycobutin) Antineoplastic and Immunosuppressive 
Antibiotics- Anti-infection 
96.66 ± 30.90 
Esomeprazole Magnesium 
(Nexium) 
proton pump 68.11 ± 20.06 
Ethionamide Anti-infection 52.59 ± 27.15 
Vidarabine (Vira-A) 5-alpha Reductase 88.61 ± 18.51 
Deferasirox (Exjade) Ferroptosis P450 (e.g. CYP17) 78.46 ± 19.75 
Methylprednisolone Immunology and Inflammation related, 
Glucocorticoid Receptor, Interleukins, 
ACE, Apoptosis related, Autophagy 
93.67 ± 25.54 
Metolazone (Zaroxolyn) Treatment congestive heart failure and 
high blood pressure 
155.75 ± 34.37 
Darunavir 
Ethanolate (Prezista) 
HIV Protease 56.94 ± 18.04 
Prednisone (Adasone) Glucocorticoid receptor 76.69 ± 23.89 
a Mean ± SD   
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Table 4.4 List of hit compounds identified from FDA screening on MRP2 protein 
expression  
Drug Target % Modulation on MRP1 
 protein levels a 
Rasagiline Mesylate MAO -58.99 ±4.72 
Dronedarone HCl  Anti-infection -56.17 ± 5.53 
Conivaptan HCl (Vaprisol) vasopressin receptor -57.59 ± 0.83 
Eltrombopag (SB497115-GR) c-mpl (TpoR) receptor 79.40 ± 18.03 
Paeoniflorin COX, HIF 53.80 ± 20.35 
Benserazide Dopamine Receptor 54.48 ± 22.74 
Lovastatin HMG-CoA Reductase 77.64 ± 17.81 
Lafutidine Histamine Receptor 55.36 ± 19.22 
Erythromycin Anti-infection, 
Antibiotics 
104 ± 18.32 





Test compounds that modulated the protein expression levels of MRP2  in MDCKII/MRP2 
cells above 50% (Hit compounds) in this study cuts across a broad spectrum of drug classes 
and exhibit great diversity in their structure, molecular targets, and mode of action. This 
included anticancer drugs, antibiotics, antivirals, anti-inflammatory drugs among others. 
This finding reaffirms the promiscuous nature of the MRP2 transporter, and how important 
it is to investigate the interaction between both old and newly developed drugs with MRP2. 
Although several studies have aimed at investigating the impact of various therapeutic 
agents on MRP2 efflux activity, it is needful that researchers also pay critical attention to 
how these drugs may affect the protein expression levels of this transporter. From our 
screening, about 10.48% of the hit compounds increased the expression of MRP2 protein 
levels, this included drugs like vincristine (an anticancer drug), oxaliplatin (antineoplastic 
medication), and irinotecan (an anticancer drug). MRP2 has been reported to be one of the 
major ABC transporters that affect the bioavailability and therapeutic potency of anticancer 
drugs in both polarized and unpolarized cells [10]. The anticancer drugs; Vincristine, 
Oxaliplatin, and Irinotecan have earlier been reported in other studies as substrates of 
MRP2 [7, 11, 12]. This indicates they are actively transported by MRP2/ABCC2 
transporter thus the increase in MRP2 protein expression as observed in this study provides 
the possible explanation that more MRP2 is expressed in these cells to catalyze and ensure 
successful transport or efflux of these drugs across the plasma membrane. 
 Glucocorticoids like dexamethasone and prednisone also upregulated MRP2 protein 
expression in our present screening. The ability of dexamethasone to increase the 
expression levels of MRP2 protein as observed from the screening also reaffirms the 
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observation reported by Narang and his colleagues [13] who reported that dexamethasone 
increased expression and activity of multidrug resistance transporters at the rat blood-brain 
barrier. Prednisone, on the other hand, has also been reported to induce the activity of the 
MRP2 promoter [14], thus providing a possible reason for the increase in MRP2 protein 
levels observed in this study. Methylprednisolone, another glucocorticoid with anti-
inflammatory and immunomodulating properties also upregulated MRP2 protein levels in 
this screening. However to the best of our knowledge, the interaction between MRP2 and 
methylprednisolone is yet to be reported, and it would be enlightening for further studies 
to be carried out to investigate how these drugs may affect MRP2 activity. Erythromycin 
(an antibiotic) and Lovastatin (a hypolipidemic agent and an HMG-CoA reductase 
inhibitor) which has been reported by other studies to be substrates of MRP2 [15, 16] also 
elevated the protein levels of MRP2 in this present study. Hence, this finding provides 
useful information on the modulatory effect of these drugs that can be further explored.  
 Furthermore, findings from this study also suggest that anticancer drugs like Pralatrexate, 
Afatinib, and Cladribine (an immunosuppressant)  may decrease MRP2 protein expression 
levels in MDCKII MRP2-overexpressing cells. Pralatrexate has been reported in earlier 
studies to act as both a substrate and an inhibitor of MRP2 [17], interestingly, results from 
our present study demonstrate that pralatrexate may downregulate the expression levels of 
MRP2. Further investigation can be conducted to provide more insight into the effect of 
pralatrexate on gene expression and other effectors that regulate MRP2 protein expression. 
Moreover, the effect of pralatrexate on MRP2 protein expression levels in other MRP2-
overexpressing cell lines can be explored to confirm this initial finding. Afatinib is a known 
moderate inhibitor of P-gp [18, 19], and a substrate /inhibitor of BCRP [19]. Results for 
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this current study shows that Afatinib may reduce MRP2 protein levels. A thorough search 
of current literature revealed that little is known about the impact of Afatinib on MRP2 
activity and protein expression. Thus it would be enlightening to conduct further 
investigation to confirm and ascertain how Afatinib affects the efflux activity of this 
transporter in other MRP2 overexpressing cells. Cladribine is an FDA approved drug used 
in the treatment of multiple sclerosis and hairy cell leukemia. It is a known substrate of 
BCRP [20, 21] but proved otherwise on MRP2 when its impact on MRP2 membrane 
vesicles was explored [22]. Nonetheless, cladribine downregulated the protein expression 
levels of MRP2 in MDCKII MRP2 overexpressing cells in our present study. Thus it would 
be illuminating to investigate the impact of cladribine on other MRP2-overexpressing cells 
since the specific interactions between Cladribine and MRP2 remain uncertain. Further 
probing using cell lines overexpressing this transporter would be a step in the right 
direction. Adrucil (Fluorouracil), a DNA and RNA synthesis inhibitor that irreversibly 
inhibits thymidylate synthase, and Asenapine, an antipsychotic medication belonging to 
the dibenzooexpinopyrrole class [23] downregulated the expression levels of MRP2 in our 
present study. To the best of our knowledge, the impact of Adrucil and Asenapine on MRP2 
activity and expression has not been reported in literature. 
Although HIV Protease Inhibitors (HPIs) have been reported to be substrates of MRP1 and 
MRP2, the majority of tested HPIs are transported by MRP2. As such the overexpression 
of MRP2 has great pharmacological implications on administered HPIs [24, 25]. Darunavir 
Ethanolate is the ethanolate form of darunavir and an antiretroviral drug that inhibits the 
human immunodeficiency virus type-1 (HIV-1) protease. In this present study, Darunavir 
Ethanolate increased MRP2 protein expression in MDCKII overexpressing MRP2 cells. 
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Although to the best of our knowledge, Darunavir Ethanolate has not been reported as a 
substrate of MRP2, its ability to increase MRP2 protein levels suggests that this 
antiretroviral drug may also be a victim of MRP2 efflux activity. Interestingly, Darunavir 
the parent compound of Darunavir Ethanolate has been reported in other studies to induce 
P-gp mRNA activity and expression in vitro as well as induce MRP1 protein expression in 
CD4 (+) T cells from healthy human volunteers [26, 27]. On the Contrary, Adefovir 
dipivoxil, a diester prodrug of adefovir and an antiviral medication used in the treatment 
of chronic Hepatitis B infection in adults, also lessened the protein levels of MRP2 in this 
screening. This is not surprising since adefovir is reported to be a known inhibitor of MRP2 
[28]. However, no information has been reported on the interaction between this diester 
derivative of adefovir and MRP2. It would be enlightening to investigate the modulatory 
effect of Darunavir Ethanolate and Adefovir dipivoxil on MRP2 activity and expression in 
other MRP2 overexpressing cells.  
Our screening also identified other novel drugs whose effect on MRP2 activity or 
expression levels are yet to be reported or explored to the best of our knowledge. This 
included glyburide (medication for diabetes), Rasagiline mesylate ( medication for 
Parkinson's disease), dronedarone HCl (antiarrhythmic drug), and conivaptan HCl 
(vasopressin antagonist, endocrine-metabolic agent). These novel drugs downregulated the 
protein expression levels of MRP2 in MDCKII MRP2-overexpressing cells in this study. 
Other non-reported drugs that upregulated the expression levels of MRP2 in our present 
study included Streptozotocin, Megestrol acetate, Gestodene, Trilostane, Ranolazine 
dihydrochloride among others. This initial data on these novel drugs would provide fore-
knowledge that can further be explored. Like most proteins, MRP2 can be regulated at the 
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transcriptional and post-transcriptional level. Studies have revealed that alterations in the 
intracellular concentrations of bile acids and of a number of lipophilic compounds that are 
ligands for nuclear hormone receptors can regulate MRP2/ABCC2 transcription levels [6]. 
Nuclear hormone receptors for hydrophobic molecules such as steroid hormones 
(estrogens, glucocorticoids, progesterone, mineralocorticoids, androgens, vitamin D3, 
ecdysone, oxysterols and bile acids), retinoic acids (all-trans and 9-cis isoforms), thyroid 
hormones, fatty acids, leukotrienes and prostaglandins [29, 30]. Research has shown that 
the hormone response element in rat  MRP2/Abcc2 promoter (ER-8) is bound by 
heterodimers of the retinoid receptor [31] with the ligand -activated transcription factors, 
pregnane X receptor (PXR), farnesoid X receptor (FXR) or constitutive androstane 
receptor (CAR). Thus various xenobiotics that regulate bile acid concentration can activate 
these receptors which in turn upregulates the promoter region of the ABCC2 transporter 
[32-36]. This finding provides a possible explanation to the increase in MRP2 protein 
expression observed in this study after MDCKII/MRP2 cells were treated with Megestrol 
acetate (androgen receptor), Gestodene (estrogen/progestogen receptor), 
Methylprednisolone and Prednisone (Glucocorticoid receptor), and Evista 
(estrogen/progestogen receptor).  
In summary, the modulatory effect of 372 drugs from a recently approved FDA drug library  
on MRP2 protein expression in MDCKII/MRP2 cells was successfully screened using In-
Cell ELISA assay. From this study, 49 hits compounds were identified to have altered  the 
MRP2 expression levels by more than 50%, representing 13.17% of total compounds 
screened. Among the identified hits for MRP2, 39 drugs increased expression levels 
whereas 10 drugs lowered expression levels of MRP2 after drug treatment. Although these 
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identified hit compounds may be substrates, inhibitors, inducers, activators of MRP2, or 
even false hits due to the non-specific interactions of MRP2 due to unknown reasons,  
findings from this study bring to light the fact that MRP2 protein expression may be 
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This chapter focuses on relevant contributions and side projects undertaken towards the 
general scholarly goals of our research group. After identifying novel modulators of MRP1 
protein expression and activity in our initial screening of 30 drugs which comprised of 
anticancer and FDA approved drugs as described earlier, we set out to screen a larger 
number of drugs from different libraries to identify more modulators of MRP1  protein 
expression. The first two projects in this session describe projects that were undertaken in 
this direction. The first project aimed at the identification of chemotherapeutic drugs as 
modulators of MRP1 protein expression in MRP1-overexpressing cells. In this project, we 
screened 383 anticancer drugs from a unique anticancer library for their modulatory effect 
on MRP1 protein expression in HEK293 MRP1-overexpressing cells using a high 
throughput In-Cell ELISA assay. Our results from this study showed that some anticancer 
drugs may modulate MRP1 protein expression and also demonstrated that the In-Cell 
ELISA assay can be used as an effective high throughput tool for screening purposes. 
Drugs that were identified can be used in developing therapeutics for treating tumors with 
the MDR phenotype conferred by MRP1 overexpression.  
The goal of the second project was to screen a recently approved FDA drug library to 
identify modulators of MRP1 protein expression in HEK293 MRP1-overexpressing cells. 
A total of 440 FDA drugs were successfully screened using In-Cell ELISA assay. These 
drugs included antibiotics, antivirals, antidepressants among others. Our findings from the 
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project suggest and affirm the fact that MRP1 interacts with a broad range of drug classes. 
This signifies the importance of profiling the interaction of drugs with this transporter, and 
the data obtained would provide essential information to improve drug efficacy and reduce 
drug toxicity of various cancer chemotherapeutics and in diseases in which MRP1 is 
implicated. In the third project, the effect of novel cucurbitacin-inspired estrone analogs 
inhibitors of P-gp and MRP1 on P-gp and MRP1 protein expression was investigated. 
These inhibitors were identified in an initial screening that was conducted by our research 
group in another project. These inhibitors were further characterized using established cell-
based methods, thus we ascertained the impact of these novel inhibitors on MRP1 and P-
gp protein expression in human embryonic kidney overexpressing P-gp cells (HEK293/P-




Identification of chemotherapeutic drugs as modulators of Multidrug Resistance 
Protein 1 (MRP1) expression in HEK293 MRP1- overexpressing cells 
Introduction 
We recently identified some novel modulators from our initial screening of thirty 
compounds on MRP1 protein expression in HEK293 MRP1-overexpressing cells. These 
drugs consisted of both clinically tested anticancer drugs and some recently approved FDA 
drugs. From our initial screening, we identified that anticancer drugs; SB743921 HCl, 
Amuvatinib, TG101348 (SAR302503), and a FDA-approved drug; Felbamate, may 
modulate MRP1 protein expression in HEK293 MRP1-overexpressing cells. Further 
characterization of these compounds using cell-based established assays revealed that 
SB743921 HCl, Amuvatinib, TG101348 downregulate MRP1 efflux activity, with 
Amuvatinib and TG101348 being potent reversers of MRP1 mediated MDR in these cells. 
Based on these interesting findings we decided to screen different drug libraries containing 
a larger number of drugs to investigate their effect on MRP1 protein expression. Using In-
Cell ELISA assay, we explored the effect of 383 clinically-tested anticancer drugs from a 
unique anticancer drug library for their effect on MRP1 protein expression in HEK293 
MRP1-overexpressing cells. These drugs from the anticancer library consisted of small 




Materials and methods 
Chemicals  
Anticancer compound library consisting of 383 anticancer small molecules under clinical 
trials for 12 different types of cancers was procured from Selleck Chemicals (Houston, 
TX). Super signal West Dura® extended duration chemiluminescence substrate 
(21EAPI34076) was purchased from Thermo Fisher Scientific (Waltham, MA). 
Cell lines and cell culture 
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modified Eagle medium 
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine 
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a 
humidified incubator maintained at 5% CO2 and 37°C. This incubation condition was 
retained in all subsequent cell culture procedures. 
 
Screening of anticancer library using  In-Cell ELISA assay  
Cells were seeded at 5x104 cells per well in 96- well plates with DMEM containing 10% 
FBS and incubated for 24 hours at 37°C. Cells were treated with drugs (10uM), 0.1% 
DMSO for controls and incubated for 48 hours at 37°C. At the end of the incubation period, 
treatment was removed and cells were rinsed twice with 150 μL of PBS. Cells were fixed 
with 3.7% paraformaldehyde and permeabilized with Triton-X 100. The cells were blocked 
with fish gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal 
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anti-MRP1 antibody (IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin 
antibody (T5168, Sigma-Aldrich) at 1:500 and 1:1000 dilutions, respectively. Secondary 
antibody incubation was performed using horseradish peroxidase-conjugated goat anti-
mouse IgG (H + L) (Thermo Fisher Scientific) for an hour at room temperature. Target 
proteins were detected using Super Signal West Dura® Extended Duration 
chemiluminescence substrate (21EAPI34076, Thermo Fisher Scientific) and read using 
Hidex Sense Beta Plus plate reader (Turku, Finland). Experiments were conducted in two 
independent studies and treatments were performed in duplicates. Dunnett test was applied 





Results and Discussion 
Screening of anticancer compound library for modulators of MRP1 protein 
expression 
The anticancer library containing 383 drugs was successfully screened using In-Cell 
ELISA assay.  Two independent experiments were conducted in the 96-well format. The 
relative MRP1-modulation activity of the anticancer drugs from the two independent 
experiments is represented as a 2D scatter plot (Figure 5.1). As indicated in Figure. 
5.1(bottom), the assay had good reproducibility with a correlation range of 0.71 between 
the two given experiments. Differences between the two groups were determined by the 
Student’s t-test using excel, and correlation analysis was evaluated by Pearson’s correlation 
using R studio version 3.5.2. Dunnett test was applied for multiple comparisons, statistical 
testing was performed at a 5% level of significance. Figure 5.2 shows the effect of the 
various anticancer drugs screened on MRP1 protein expression in HEK293/MRP1 cells. 
Screening of the 383 anticancer drugs revealed 89 hit compounds that changed the MRP1 
expression by 50% or more, representing 23.2% of total compounds screened. Among the 
identified hits, 57 drugs increased expression whereas 32 drugs lowered expression of 
MRP1 after drug treatment as shown in Figure 5.3.  The identified hit compounds included 
known MRP1 substrates like doxorubicin, vincristine, etoposide, and dexamethasone [1, 
2]. Some novel MRP1 modulators were also identified in this initial screening whose 
interaction or relationship with MRP1 have not been reported. These novel modulators may 
be substrates, inhibitors, inducers, or activators of MRP1. Some may also be false hits due 
to the non-specific interaction with MRP1 for unknown reasons. However, these novel 
142 
 
modulators identified would be further validated and characterized by our research group 
in future studies.  
 
Correlation coefficient  
Experiment                              1                                         2 
           1                                        1                                        0.71 
       2                                    0.71                                         1 
 
Figure 5.1 Screening of Anticancer drug library using In-Cell ELISA assay  
The screening was conducted in two independent studies at a compound concentration of 
10uM. The table below the plot shows correlation coefficients between the experiments. 




Figure 5.2 Effect of Anticancer drugs on MRP1 protein expression levels in 
HEK293/MRP1 cells from screening using In-Cell ELISA assay 
 
Figure 5.3 Screening of 383 anticancer drug library using In-Cell ELISA assay 
Eighty-nine (23.24%) hit compounds modulated the MRP1 expression levels, with 57 
(14.88%) drugs increased expression levels whereas 32 (8.36%) drugs lowered expression 
levels of MRP1 after drug treatment.  
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Identification of FDA approved drugs as modulators of Multidrug Resistance Protein 
1 (MRP1/ABCC1) expression in MRP1-overexpressing cells 
Introduction 
MRP1 is reported to affect the efficacy and bioavailability of drugs belonging to various 
drug classes aside from anticancer drugs [3]. We decided to explore the effect of other 
therapeutic agents from other drug families on MRP1 protein expression in HEK293 
MRP1-overexpressing cells. We achieved this by screening 440 FDA drugs from a recently 
approved FDA drug library to ascertain their effect on MRP1 protein expression. This FDA 
approved drug library consisted of structurally diverse therapeutic agents that belonged to 
different drug families. This includes antivirals, antibiotics, antidepressants, anti-





Materials and methods 
Chemicals  
FDA (Food and Drug Administration) approved drug library was procured from Selleck 
chemicals (Houston, TX). Super signal West Dura® extended duration chemiluminescence 
substrate (21EAPI34076) was purchased from Thermo Fisher Scientific (Waltham, MA). 
 
Cell lines and cell culture 
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modified Eagle medium 
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine 
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a 
humidified incubator maintained at 5% CO2 and 37 °C. This incubation condition was 
retained in all subsequent cell culture procedures. 
 
Screening of FDA approved drug library using In-Cell ELISA assay  
In-Cell ELISA assay was performed by seeding  HEK293/pcDNA 3.1 and HEK293/MPR1 
cells at a cell density of 5x104 cells per well in 96- well plates with Dulbecco’s  Modified 
Eagle Medium supplemented with 10% fetal bovine serum. Cells were treated with 
drugs(10uM), DMSO (control and Parental) after 24 hours (95% confluency), and 
incubated for 48 hours at 37 °C. At the end of the incubation period, treatment was removed 
and cells were rinsed twice with 150 μL of PBS. Cells were fixed with 3.7% 
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paraformaldehyde and permeabilized with Triton-X 100. The cells were blocked using fish 
gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal anti-
MRP1 antibody (IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin antibody 
(T5168, Sigma-Aldrich) at a 1:1000 dilution, respectively. Secondary antibody incubation 
was performed using horseradish peroxidase-conjugated goat anti-mouse IgG (H + L) 
(Thermo Fisher Scientific) at a dilution of 1:1000 for an hour at room temperature. Target 
proteins were detected using Super Signal West Dura® extended duration 
chemiluminescence substrate (21EAPI34076, Thermo Fisher Scientific), and read using 
Hidex Sense Beta Plus plate reader (Turku, Finland). Treatment was performed in 
triplicates. Data obtained were statistically analyzed to calculate the mean and percentage 
modulation. Drugs that showed modulation above 50% were considered as Hit compounds. 
  
Results and discussion 
 Screening of FDA approved drug library for modulators of MRP1 
The FDA approved drug library containing 440 drugs was successfully screened using In-
Cell ELISA assay. The FDA approved drug library was screened using HEK293 MRP1-
overexpressing cells. Treatments were performed in triplicates, and experiments were done 
using the 96-well format. The relative MRP1-modulation activity of the FDA approved 
drugs are shown according to plates screened as presented in Figure 5.4. The mean and 
percentage modulation of the drugs screened were calculated using Microsoft excel. Drugs 
showing more than 50% modulation on MRP1 were selected as hit compounds. Screening 
of the 440 FDA-approved drugs on HEK293/MRP1 cells revealed 70 hit compounds that 
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modulated the MRP1 expression levels by 50% or more representing 15.90% of total 
compounds screened. Among the identified hits, 56 drugs increased expression levels 
whereas 14 drugs lowered expression levels of MRP1 after drug treatment as shown in 
Figure 5.5. Findings from our initial screening showed that aside anticancer drugs, drugs 
from other drug classes can also modulate MRP1 protein expression. The identified hit 
compounds included antivirals, anticonvulsants, anti-inflammatory, antiestrogen agents 
among others. The modulators identified in this study would be further investigated and 
characterized by our research group in future projects.  
 
Figure 5.4: Screening of 440 FDA  approved drug library using In-Cell ELISA assay 
Seventy hits compounds (15.91%) changed the MRP1 protein expression by more than 
50%. Fifty-six drugs (12.73%) increased expression levels whereas 14 drugs (3.18%) 




Figure 5.5: Screening of 440 FDA  approved drug library using In-Cell ELISA assay 
Seventy  (70) hit compounds (15.91%) that changed the MRP1 expression levels by more 
than 50%. 56 drugs (12.73%) increased expression levels whereas 14 drugs (3.18%) 





Effect of novel cucurbitacin-inspired estrone analogs on the protein expression levels 
of P-glycoprotein (P-gp) and Multidrug resistance protein 1 (MRP1)  
Introduction 
Natural compounds including phytochemicals have been established as compounds that 
can modulate the activity of ABC transporters including MRP1 and P-gp. Polyphenols like 
curcumin, and bioflavonoids like apigenin, quercetin have been reported to have a 
significant effect on the transport activity of MRP1 [4, 5]. Recently, in an ongoing project, 
we screened some cucurbitacin-inspired estrone analogs to identify inhibitors of P-
glycoprotein (P-gp) and Multidrug resistance protein 1 (MRP1) in human embryonic 
kidney overexpressing P-gp cells (HEK293/P-gp) and small cell lung cancer cell line 
(H69AR) respectively. We identified 8 of these analogs to show inhibitory effects on P-gp 
activity in HEK293/P-gp whereas 4 of these analogs also strongly inhibited MRP1 in 
H69AR. These inhibitors have further been characterized using established cell-based 
assays. We further investigated the influence of these novel inhibitors on P-gp and MRP1 




Materials and methods 
Cell lines and cell culture 
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293/pcDNA3.1 
and HEK293/P-gp were kindly gifted by Dr. Suresh V. Ambudkar (NIH, Bethesda, MD). 
Dulbecco’s modified Eagle medium (DMEM) (GE Healthcare, Marlborough, MA, USA) 
supplemented with 10% fetal bovine serum (FBS) was used to grow the HEK293 cell lines. 
H69 cell lines were cultured in RPMI 1640 (ATCC) media supplemented with 10% FBS. 
H69AR cells were monthly exposed to 0.8 mM doxorubicin and cultured without drug 
treatment for 1 week before use in experiments. Cells were cultured at 37 °C in a 
humidified incubator set at 5% CO2. 
 
Western blot assay 
HEK293 and H69 cell lines were seeded at cell densities of  7x105 and 1x106 cells in 6-
well plates respectively in a culture medium. Cells were treated with drugs (10 µM), and 
0.1% DMSO for controls after 24 hours, and incubated for 48 hours at 37 °C after drug 
treatment. At the end of the incubation period, treatments were removed and cells were 
rinsed with 1000 μL of  PBS. The cells were lysed with lysis buffer containing RIPA buffer 
(Thermo Fisher Scientific, Waltham, MA) supplemented with 1× halt protease inhibitor. 
Protein concentration was determined with the Pierce BCA protein assay kit (Thermo 
Fisher Scientific, Waltham, MA). Proteins (20 μg)  were loaded in each well on 8.0% mini 
sodium dodecyl sulfate (SDS) gels, and SDS page electrophoresis was conducted. Proteins 
were transferred to Immobilon PVDF membranes (EMD Millipore, Burlington, MA). The 
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membrane was blocked and incubated overnight at 4 °C with rabbit monoclonal anti-MRP1 
antibody [EPR21062](1:250; Abcam, ab233383) and anti-alpha-tubulin antibody (1:5000; 
Sigma-Aldrich) respectively. Followed by incubation with secondary antibody for an hour 
at room temperature using horseradish peroxidase-conjugated goat anti-mouse IgG(H+L) 
(1:1000; Thermo Fisher Scientific) for alpha-tubulin, and horseradish peroxidase-
conjugated goat-anti-rabbit IgG(H+L) (1:1000; Thermo Fisher, Scientific) for detection of 
MRP1. Target proteins were developed using a Western blotting luminol reagent (Santa 
Cruz Biotechnology, sc-2048) and an LI-COR Odyssey Fc imaging system. Protein band 
densities were quantified and analyzed using Image Studio Lite version 5.2 (LI-COR 
Biotechnology, Lincoln, NE), and uneven sample loading and transfer was corrected using 
the intensity of the corresponding protein band relative to the alpha-tubulin (loading 
control) band. The experiment was conducted in three independent studies. The data 
obtained was statistically analyzed and the Dunnett test was applied for multiple 




Results and Discussion 
 Effect of test compounds on P-gp and MRP1 protein expression levels 
We determined the effect of these novel cucurbitacin-inspired estrone analogs which were 
identified as inhibitors in our initial screening on protein expression of P-gp and MRP1. 
Our results as shown in Figure 5.6 and Figure 5.7 indicate that these inhibited do not have 
a significant impact on P-gp and MRP1 protein expression in HEK293/P-gp and H69AR 
cells. 
Figure 5.6: Effect of novel cucurbitacin-inspired estrone analogs on protein expression of 
P-gp in HEK293/P-gp cells 
[A, B] Shown are representative western blots of whole-cell lysates (20 ug of protein/lane) 
prepared from drug treatment (10 uM) on HEK293/P-gp cells. P-gp proteins  and alpha-
tubulin was detected using monoclonal P-gp antibody [C219] (GTX23364,GeneTex) and 
anti- alpha-tubulin antibody  (Sigma-Aldrich) at 1:250 and 1:5000 dilutions, respectively. 
Secondary antibody incubation used performed using GAM (mAb – goat- anti-mouse) 
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(1:10000). [C, D] Dunnett test was applied for multiple comparisons, statistical testing was 
performed at a 5% level of significance, and the graph was developed using Graph Pad 
Prism version 6. 
  
     
Figure 5.7 Effect of novel cucurbitacin-inspired estrone analogs on protein expression 
MRP1in H69AR cells. 
 [A] Shown are representative western blots of whole-cell lysates (20 ug of protein/lane) 
prepared from H69AR cells treated 10 µM of test compounds. MRP1 proteins were 
detected with monoclonal anti-MRP1 antibody [EPR21062](ab233383, Abcam) and anti-
GAPDH antibody (Sigma-Aldrich) at a dilution of 1:250 and 1:1000 respectively. 
Secondary antibodies; mAb - anti-rabbit and mAb-anti-goat were used at a dilution of 
1:1000. [B] Dunnett test was applied for multiple comparisons, statistical testing was 
performed at a 5% level of significance, and graph was developed using Graph Pad Prism 
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Final discussions and General conclusions 
The overexpression of ABC transporters in tumor cells has been reported to be responsible 
for the multidrug resistance (MDR) phenotype observed in several carcinomas. The role of 
ABC transporters like P-gp and BCRP in the MDR of tumor cells has been well 
investigated in clinical cancer research. However, recent studies have revealed that ABC 
transporters; MRP1 and MRP2 are also major players in the development of MDR in 
several carcinomas [1, 2]. MRP1 was discovered by Cole and her colleagues when they 
observed the overexpression of a transporter gene in a multidrug-resistant human lung 
cancer cell line (H69AR) which did not overexpress P-gp [3]. The plasticity of the binding 
site of this transporter enables it to interact with a variety of substrates, which mostly 
include amphipathic organic acids with large hydrophobic groups [4]. This ubiquitous 
transporter is reported to mediate the transport of heavy metals, organic anions, 
glucuronide-conjugates of steroids, prostaglandins, drugs, and their metabolites across 
biological membranes [5, 6]. Due to its transport activity, MRP1 governs the absorption 
and disposition of drugs and their metabolites across cells. MRP2 which is popularly 
known as canicular multi-specific organic anion transporter 1 (cMOAT) [7] also facilitates 
the transport of xenobiotics and endogenous compounds to the bile, urine, or feces [8]. Due 
to the pivotal roles of MRP1 and MRP2 in the transport and distribution of drugs and their 
metabolites, their overexpression has been associated with reduced intracellular 
concentration and bioavailability of various classes of drugs (vinca alkaloids, 
anthracyclines, antibiotics, protease inhibitors) [8-11] in tumor cells. As such, these 
transporters have been implicated in MDR of several solid human tumors like kidney, 
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colon, breast, lung, and ovarian carcinomas [12]. Strategies to overcome the MRP1 and 
MRP2 mediated MDR in tumors involve the identification of modulators of these 
transporters which can regulate their activities in tumor cells without interrupting their role 
in maintaining physiological equilibrium in normal cells. Although some modulators of 
MRP1 and MRP2 have been identified in recent times, most of the current modulators that 
have been identified are limited by non-specific toxicity, low MDR reversal effects, and 
low therapeutic efficacy in in-vivo experiments. Thus there is the need for the identification 
of more potent and safer modulators of MRP1 and MRP2.  
In this present study, we aimed at identifying modulators of MRP1 and MRP2 by screening 
therapeutic agents from various drug libraries using In-Cell ELISA assay. Our initial 
screening of 30 compounds, identified a total of 7 test compounds that modulated MRP1 
protein expression in HEK293 MRP1-overexpressing cells by 50% or more. Four of the 
test compounds; Vismodegib (GDC-0449), TG101348 (SAR302503), Amuvatinib, and 
SB743921 HCl decreased the protein expression levels of MRP1, and three test 
compounds; Epirubicin HCl, Felbamate, and Irinotecan increased the protein expression of 
MRP1. Three of these modulators (Epirubicin HCl, Irinotecan, Vismodegib (GDC-0449) 
had already been reported in other studies [13-15], thus were not considered for further 
characterization in this study. Four of the identified modulators exerted novel modulatory 
activity on MRP1 protein expression. This included ATP competitive inhibitors; 
SB743921 HCl, Amuvatinib, TG101348 (SAR302503), and Felbamate ( a recently 
approved FDA drug). SB743921 HCl, Amuvatinib,  and TG101348 (SAR302503) 
downregulated MRP1 protein expression in HEK293 MRP1-overexpressing cells whereas 
Felbamate increased MRP1 protein expression. Our findings from this study also showed 
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that SB743921 HCl and Amuvatinib decreased MRP1 protein expression in HEK293 
MRP1-overexpressing cells in a concentration and time-dependent manner. SB743921 
HCl, Amuvatinib, and TG101348 (SAR302503) inhibited the growth of these cells at 
clinically achievable concentrations. Moreover, we report that  Amuvatinib and TG101348 
(SAR302503) reverse MRP1 mediated resistance against vincristine in HEK293 MRP1-
overexpressing cells.  
We also demonstrated that for the first time that Tie2 kinase inhibitor can inhibit MRP1 
mediated calcein efflux in HEK293 MRP1-overexpressing cells. Moreover, Tie2 kinase 
inhibitor was able to reduce the fold resistance of  HEK293 MRP1-overexpressing cells 
towards vincristine. Everolimus, an mTOR inhibitor that was previously reported by our 
lab group to be an inhibitor of MRP1 in H69AR cells, also inhibited MRP1 mediated 
calcein efflux in HEK293 MRP1-overexpressing cells. Everolimus also reversed MRP1 
mediated resistance in HEK293 MRP1-overexpressing cells. Findings from this study 
show that these therapeutic agents may be useful for developing combinatorial therapy 
targeting malignancies involving MRP1. 
 Furthermore, we also screened a recently approved FDA approved library for modulators 
of MRP2 using In-Cell ELISA. This unique FDA drug library comprises drugs from 
different drug classes including antivirals, antibiotics, antidepressants, antihypertensives 
among others. Our screening of 372 FDA drugs identified 49 modulators of MRP2 in 
MDCKII MRP2-overexpressing cells. Thirty-nine of these modulators increased MRP2 
expression whereas 10 compounds lowered MRP2 expression levels after drug treatment. 
The ability of MRP2 to be modulated by compounds from different drug families that 
exhibit great structural diversity in this study indicates that MRP2 is a promiscuous 
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transporter. As such this transporter can interact with several compounds irrespective of 
their structure and drug classification. Modulators identified in this study would be further 
characterized in future projects.  
On the whole, we identified modulators of MRP1 and MRP2 protein expression and 
activity. These modulators can be used in the development of combinatorial drug therapy 
for MRP1 and MRP2 targeted therapeutics. Our findings indicate the importance of 
investigating the possible drug-interactions between various therapeutic compounds with 
these transporters. Research into drug-transporter interactions would provide a better 
understanding of the physiology of these transporters and the pharmacology of these 
therapeutic agents. Thereby creating a platform for optimizing drug treatment for 
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